American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation

The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients...

Full description

Saved in:
Bibliographic Details
Published inTransplantation and cellular therapy Vol. 27; no. 9; pp. 707 - 719
Main Authors Hakki, Morgan, Aitken, Samuel L., Danziger-Isakov, Lara, Michaels, Marian G., Carpenter, Paul A., Chemaly, Roy F., Papanicolaou, Genovefa A., Boeckh, Michael, Marty, Francisco M.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.09.2021
Subjects
Cytomegalovirus
Guideline
Hematopoietic cell transplant
Preemptive therapy
Prevention
Prophylaxis
Prevention
Cytomegalovirus
Guideline
Hematopoietic cell transplant
Prophylaxis
Preemptive therapy
Online AccessGet full text
ISSN2666-6367
2666-6367
DOI10.1016/j.jtct.2021.05.001

Cover

Abstract The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients. A new approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed and answered FAQs. Topics were finalized with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. The third topic in the series focuses on the prevention of cytomegalovirus infection and disease in HCT recipients by reviewing prophylaxis and preemptive therapy approaches; key definitions, relevant risk factors, and diagnostic monitoring considerations are also reviewed.
AbstractList The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients. A new approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed and answered FAQs. Topics were finalized with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. The third topic in the series focuses on the prevention of cytomegalovirus infection and disease in HCT recipients by reviewing prophylaxis and preemptive therapy approaches; key definitions, relevant risk factors, and diagnostic monitoring considerations are also reviewed.
The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients. A new approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed and answered FAQs. Topics were finalized with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. The third topic in the series focuses on the prevention of cytomegalovirus infection and disease in HCT recipients by reviewing prophylaxis and preemptive therapy approaches; key definitions, relevant risk factors, and diagnostic monitoring considerations are also reviewed.The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients. A new approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed and answered FAQs. Topics were finalized with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. The third topic in the series focuses on the prevention of cytomegalovirus infection and disease in HCT recipients by reviewing prophylaxis and preemptive therapy approaches; key definitions, relevant risk factors, and diagnostic monitoring considerations are also reviewed.
Author Aitken, Samuel L.
Chemaly, Roy F.
Danziger-Isakov, Lara
Papanicolaou, Genovefa A.
Carpenter, Paul A.
Marty, Francisco M.
Hakki, Morgan
Boeckh, Michael
Michaels, Marian G.
Author_xml – sequence: 1
  givenname: Morgan
  surname: Hakki
  fullname: Hakki, Morgan
  email: hakki@ohsu.edu
  organization: Division of Infectious Diseases, Department of Medicine, Oregon Health and Science University, Portland, Oregon
– sequence: 2
  givenname: Samuel L.
  surname: Aitken
  fullname: Aitken, Samuel L.
  organization: Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas
– sequence: 3
  givenname: Lara
  surname: Danziger-Isakov
  fullname: Danziger-Isakov, Lara
  organization: Division of Infectious Disease, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio
– sequence: 4
  givenname: Marian G.
  surname: Michaels
  fullname: Michaels, Marian G.
  organization: Division of Pediatric Infectious Diseases, Department of Pediatrics, UPMC Children's Hospital of Pittsburgh and the University of Pittsburgh, Pittsburgh, Pennsylvania
– sequence: 5
  givenname: Paul A.
  surname: Carpenter
  fullname: Carpenter, Paul A.
  organization: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
– sequence: 6
  givenname: Roy F.
  surname: Chemaly
  fullname: Chemaly, Roy F.
  organization: Department of Infectious Diseases, Infection Control, & Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas
– sequence: 7
  givenname: Genovefa A.
  surname: Papanicolaou
  fullname: Papanicolaou, Genovefa A.
  organization: Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York
– sequence: 8
  givenname: Michael
  surname: Boeckh
  fullname: Boeckh, Michael
  organization: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
– sequence: 9
  givenname: Francisco M.
  surname: Marty
  fullname: Marty, Francisco M.
  organization: Division of Infectious Diseases, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts
BookMark eNqFkU9uEzEUhy3USpTSC7CyxIZNBv-JPUnFJgqUVqpEpZa15XiewcFjD7YTaXY9RG_Qm3ESnAYhlEVZ2Zbf937P_l6hoxADIPSGkoYSKt-vm3UxpWGE0YaIhhD6Ap0wKeVEctke_bN_ic5yXhNC2JQTyskJelz0kJzRAd9G46CM2MaE75IOefA6FF1cDFiHDi_B-43X9fI7JD2M-LaCkM_xW_7r_uEmwRbCU3G0eDmW2MM37ePWpU3GV8GC-dvpo8ugM-CFLZDwJfS6xCHWcGeeUg7jX6Njq32Gsz_rKfp68elueTm5_vL5arm4npipIGXSyZauDAXNLNCOt51d0VbIFZMraeuBEG5aLqxp7WzGDeWdEC2nxsxbMWdG8lP0bt93SPHnBnJRvcumDqQDxE1WTEhJpnQ6m9fS2b7UpJhzAquM2w9bknZeUaJ2atRa7dSonRpFhKpqKsoO0CG5XqfxeejDHoL6_q2DpHK1FQx0LtWfVV10z-PnB7jxLlTt_geM_4N_AzUOwnk
CitedBy_id crossref_primary_10_1016_j_cmi_2024_06_020
crossref_primary_10_1093_cid_ciae113
crossref_primary_10_1093_jpids_piad059
crossref_primary_10_1016_j_cmi_2023_07_026
crossref_primary_10_1093_cid_ciae114
crossref_primary_10_1038_s41409_024_02313_3
crossref_primary_10_1182_bloodadvances_2023010966
crossref_primary_10_1007_s40121_024_00917_2
crossref_primary_10_1080_17512433_2023_2259308
crossref_primary_10_1016_j_jtct_2023_12_013
crossref_primary_10_12677_ACM_2023_1391974
crossref_primary_10_1016_j_jtct_2025_01_883
crossref_primary_10_3389_fped_2024_1394006
crossref_primary_10_1111_tid_14358
crossref_primary_10_1016_j_jtct_2024_12_010
crossref_primary_10_3389_fimmu_2023_1226148
crossref_primary_10_1097_QCO_0000000000001065
crossref_primary_10_1097_TP_0000000000004856
crossref_primary_10_1016_j_transproceed_2024_08_028
crossref_primary_10_1182_bloodadvances_2022009376
crossref_primary_10_1007_s40262_024_01392_1
crossref_primary_10_1182_bloodadvances_2022007596
crossref_primary_10_1093_ajhp_zxae307
crossref_primary_10_20344_amp_21441
crossref_primary_10_1080_14787210_2024_2322439
crossref_primary_10_1111_bjh_19451
crossref_primary_10_1016_j_jtct_2023_12_001
crossref_primary_10_1146_annurev_med_042921_124739
crossref_primary_10_1080_10428194_2024_2371474
crossref_primary_10_1016_j_isci_2022_105065
crossref_primary_10_1186_s12985_024_02421_y
crossref_primary_10_1038_s41409_023_02081_6
crossref_primary_10_1080_03007995_2023_2222583
crossref_primary_10_1080_1744666X_2023_2161510
crossref_primary_10_1080_10428194_2022_2064992
crossref_primary_10_1080_14656566_2024_2353627
crossref_primary_10_1007_s10096_024_04977_7
crossref_primary_10_1093_cid_ciae535
crossref_primary_10_1016_j_cmi_2022_07_001
crossref_primary_10_1016_j_japh_2023_05_015
crossref_primary_10_1177_20406207241245190
crossref_primary_10_1111_tid_14290
crossref_primary_10_1128_aac_01550_22
crossref_primary_10_1093_jpids_piad075
crossref_primary_10_21926_obm_transplant_2303195
crossref_primary_10_1111_tid_14171
crossref_primary_10_3390_diagnostics14212461
crossref_primary_10_47102_annals_acadmedsg_2024178
crossref_primary_10_1080_03007995_2023_2191477
crossref_primary_10_3390_antibiotics12030592
crossref_primary_10_1182_bloodadvances_2023012175
crossref_primary_10_3389_fimmu_2024_1323923
crossref_primary_10_1002_pbc_30608
crossref_primary_10_1016_j_jtct_2024_05_019
crossref_primary_10_3390_tropicalmed9020049
crossref_primary_10_1093_ofid_ofad169
crossref_primary_10_3390_v16121884
crossref_primary_10_1007_s00277_023_05474_1
crossref_primary_10_1016_j_jtct_2022_04_016
crossref_primary_10_1111_petr_14526
crossref_primary_10_1111_tid_14101
crossref_primary_10_1016_j_cmi_2022_05_034
crossref_primary_10_1016_j_ccm_2024_10_010
crossref_primary_10_1016_j_jtct_2023_03_006
crossref_primary_10_1111_tid_14104
crossref_primary_10_1111_tid_14149
crossref_primary_10_12677_ACM_2023_1371579
crossref_primary_10_3389_fimmu_2023_1287456
crossref_primary_10_1093_cid_ciad709
crossref_primary_10_1002_jmv_29061
crossref_primary_10_1111_tid_14147
crossref_primary_10_1111_ctr_15375
Cites_doi 10.1182/blood.V99.8.3050
10.1111/j.1365-2141.2010.08227.x
10.1016/j.bcmd.2007.07.003
10.1016/j.bbmt.2012.05.015
10.1086/338624
10.1182/blood.V90.6.2502
10.1016/j.bbmt.2017.09.018
10.1093/infdis/jiz141
10.1046/j.1365-2141.1997.2773094.x
10.1016/j.bbmt.2012.06.008
10.1182/blood.V99.11.3916
10.1093/infdis/jiy592
10.1111/tid.13096
10.1016/j.bbmt.2007.02.004
10.1016/j.bbmt.2018.05.001
10.1073/pnas.140123497
10.1016/j.eclinm.2021.100787
10.1093/infdis/jiy083
10.1016/S0140-6736(94)91835-X
10.1182/blood.V86.7.2815.2815
10.1182/blood-2010-01-262089
10.1038/sj.bmt.1705825
10.1002/cpdd.388
10.1056/NEJM198801143180202
10.1016/S1083-8791(00)70010-3
10.1016/j.bbmt.2018.02.006
10.1371/journal.pone.0074744
10.1093/cid/ciy696
10.1093/infdis/jix360
10.1093/infdis/jix357
10.1182/blood-2015-11-679639
10.1182/blood-2015-08-663823
10.1182/blood.V94.12.4029
10.1093/jac/dkz218
10.2147/IDR.S296927
10.1200/JCO.2005.09.117
10.1038/sj.bmt.1705249
10.1373/49.10.1683
10.1128/AAC.00274-21
10.1016/j.bbmt.2020.01.027
10.1111/tid.12398
10.1038/s41409-020-01166-w
10.1126/scitranslmed.aaf9387
10.1182/blood.2020009362
10.1016/j.bbmt.2016.08.003
10.1002/rmv.2017
10.1111/ajt.16450
10.1038/sj.bmt.1701827
10.1016/j.bbmt.2012.02.008
10.1016/j.bbmt.2020.07.002
10.1182/blood.V97.2.388
10.1038/sj.bmt.1702450
10.1038/s41409-020-01082-z
10.1038/sj.bmt.1703251
10.1093/cid/ciw668
10.1111/j.1399-3062.2005.000111.x
10.1128/JVI.00747-19
10.1056/NEJM198604173141602
10.1016/j.jpeds.2018.04.043
10.1038/bmt.2015.303
10.1038/sj.bmt.1705699
10.1093/jac/dkz499
10.1053/j.seminhematol.2018.04.011
10.1111/bcp.13376
10.1093/cid/ciu364
10.1182/blood.V99.4.1159
10.1016/j.jinf.2015.11.005
10.1186/s12879-017-2854-2
10.1182/blood-2005-09-3786
10.1016/j.jtct.2020.10.004
10.1182/blood-2013-05-499830
10.1038/bmt.2013.164
10.7326/M19-2511
10.1182/blood-2009-02-203307
10.1038/bmt.2016.69
10.1046/j.1537-2995.2001.41101310.x
10.1111/j.1399-3046.2008.01084.x
10.1056/NEJMoa1706640
10.1093/infdis/164.3.483
10.1016/j.bbmt.2004.11.016
10.1038/s41409-019-0730-y
10.1038/sj.bmt.1700649
10.1093/infdis/166.3.473
10.1182/blood-2008-06-161695
10.1111/j.1399-3062.2011.00706.x
10.1007/s12185-010-0597-6
10.1128/JCM.00797-08
10.1038/sj.bmt.1704334
10.1182/bloodadvances.2018016493
10.1002/jmv.21727
10.1086/516484
10.1111/ctr.13512
10.1128/JCM.01670-06
10.1016/j.bbmt.2011.05.015
10.1038/sj.bmt.1701095
10.1111/ctr.13866
10.1056/NEJMoa1703327
10.1182/blood-2002-03-0932
10.1182/blood.V98.5.1626
10.1111/tid.13049
10.1016/j.bbmt.2009.02.009
10.1002/jcph.1094
10.1038/sj.bmt.1705341
10.1080/00365540110080412
10.1080/14760584.2018.1526085
10.1038/sj.bmt.1703916
10.1093/cid/cis818
10.1053/tmrv.2001.19946
10.1182/blood-2018-01-828277
10.1093/infdis/174.5.907
10.1182/blood.V82.5.1672.bloodjournal8251672
10.1111/j.1399-3062.2006.00183.x
10.1093/jpids/piz050
10.1016/S2352-3026(15)00246-X
10.1016/j.bbmt.2020.04.002
10.1016/j.bbmt.2012.07.003
10.1111/j.1399-3062.2010.00504.x
10.1038/sj.bmt.1702226
10.1182/blood-2012-08-448977
10.1182/blood-2011-06-361618
10.1016/j.bbmt.2010.07.026
10.1056/NEJMoa1714656
10.1128/AAC.01623-15
10.1093/ofid/ofw107
10.1007/s00277-015-2423-y
10.1182/blood.V86.9.3598.bloodjournal8693598
10.1016/j.vaccine.2018.02.089
10.1093/infdis/jiz577
10.7326/M13-2729
10.1111/tid.13548
10.1016/j.cmi.2015.11.006
10.1182/blood-2013-02-487074
10.1182/blood-2013-02-486324
10.1017/S0950268808000551
10.1016/j.bbmt.2018.09.038
10.1182/blood.V99.12.4357
10.1007/s00277-020-04362-2
10.1016/j.bbmt.2014.05.029
10.1016/S2352-3026(15)00289-6
10.1111/ajt.15764
10.1097/00007890-199811270-00012
10.1038/sj.bmt.1703513
10.1182/blood-2002-03-0993
10.7326/0003-4819-118-3-199302010-00003
10.1182/blood.V93.5.1781
10.1016/j.bbmt.2015.07.019
10.1111/bcp.13292
10.1038/bmt.2016.216
10.1016/j.bbmt.2018.05.008
10.1016/j.bbmt.2011.08.014
10.1086/367836
10.1093/cid/ciz490
10.1182/blood.V88.10.4063.bloodjournal88104063
10.1111/tid.13187
10.1097/TP.0000000000002396
10.1016/j.bbmt.2007.06.006
10.1002/jcph.1423
10.1111/tid.12629
10.1182/blood-2002-10-3143
10.1016/j.bbmt.2020.10.009
10.1182/blood.2020009396
10.1038/sj.bmt.1705311
10.1111/j.1399-3062.2006.00171.x
10.6004/jnccn.2016.0093
10.1111/j.1462-5822.2012.01774.x
10.1016/S0140-6736(03)14634-X
10.1097/00007890-199707150-00020
10.7326/0003-4819-118-3-199302010-00004
10.3324/haematol.2016.149880
10.1182/blood-2016-04-713644
10.1038/bmt.2016.89
10.1182/blood.V67.4.1162.1162
ContentType Journal Article
Copyright 2021 The American Society for Transplantation and Cellular Therapy
Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2021 The American Society for Transplantation and Cellular Therapy
– notice: Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
7X8
DOI 10.1016/j.jtct.2021.05.001
DatabaseName CrossRef
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
EISSN 2666-6367
EndPage 719
ExternalDocumentID 10_1016_j_jtct_2021_05_001
S2666636721008927
GroupedDBID .1-
.FO
0R~
1P~
53G
AAAJQ
AAEDW
AALRI
AATTM
AAXKI
AAXUO
AAYWO
ABJNI
ABUDA
ACIEU
ACRLP
ACVFH
ADCNI
ADVLN
AEBSH
AEHWI
AEIPS
AEUPX
AFJKZ
AFPUW
AFRHN
AFXIZ
AGCQF
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
APXCP
AXJTR
BNPGV
CJTIS
EBS
EFJIC
EFKBS
FDB
FYGXN
M41
ROL
SPCBC
SSH
SSI
SSU
T5K
Z5R
ABLVK
AFKWA
EFLBG
AAYXX
AGRNS
CITATION
7X8
ID FETCH-LOGICAL-c450t-d671bc1ea2fe1d37dfb1756b26b6fdfb003c735fc7f883c13d55731cc97592c63
IEDL.DBID AIKHN
ISSN 2666-6367
IngestDate Tue Aug 05 11:20:31 EDT 2025
Tue Jul 01 02:43:06 EDT 2025
Thu Apr 24 23:10:09 EDT 2025
Fri Feb 23 02:43:27 EST 2024
Tue Aug 26 17:49:13 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords Prevention
Cytomegalovirus
Guideline
Hematopoietic cell transplant
Prophylaxis
Preemptive therapy
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c450t-d671bc1ea2fe1d37dfb1756b26b6fdfb003c735fc7f883c13d55731cc97592c63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Instructional Material/Guideline-2
ObjectType-Feature-3
content type line 23
OpenAccessLink https://www.clinicalkey.com/#!/content/1-s2.0-S2666636721008927
PQID 2566041489
PQPubID 23479
PageCount 13
ParticipantIDs proquest_miscellaneous_2566041489
crossref_citationtrail_10_1016_j_jtct_2021_05_001
crossref_primary_10_1016_j_jtct_2021_05_001
elsevier_sciencedirect_doi_10_1016_j_jtct_2021_05_001
elsevier_clinicalkey_doi_10_1016_j_jtct_2021_05_001
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2021
2021-09-00
20210901
PublicationDateYYYYMMDD 2021-09-01
PublicationDate_xml – month: 09
  year: 2021
  text: September 2021
PublicationDecade 2020
PublicationTitle Transplantation and cellular therapy
PublicationYear 2021
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Goodrich, Bowden, Fisher, Keller, Schoch, Meyers (bib0068) 1993; 118
Han (bib0176) 2007; 45
Nichols, Price, Gooley, Corey, Boeckh (bib0029) 2003; 101
Tischer, Engel, Fritsch (bib0171) 2015; 94
Aversa, Terenzi, Tabilio (bib0159) 2005; 23
Goldsmith, Slade, DiPersio (bib0167) 2016; 101
Ljungman, Boeckh, Hirsch (bib0003) 2017; 64
Zhou, Longmate, Lacey (bib0033) 2009; 113
Boeckh, Stevens-Ayers, Bowden (bib0109) 1996; 174
Marty, Ljungman, Chemaly (bib0123) 2020; 20
Liu, Freed, Li (bib0134) 2019; 93
Lindsay, Othman, Kerridge (bib0017) 2021; 23
Verma, Devine, Morrow (bib0106) 2003; 31
Boeckh, Gooley, Myerson, Cunningham, Schoch, Bowden (bib0178) 1996; 88
Ksouri, Eljed, Greco (bib0044) 2007; 9
Miller, Flynn, McCullough (bib0155) 1986; 67
Diamond, La Rosa, Chiuppesi (bib0137) 2018; 17
Einsele, Ehninger, Steidle (bib0175) 1993; 82
Walker, van Burik, De For, Weisdorf (bib0173) 2007; 13
Pollack, Heugel, Xie (bib0071) 2011; 17
Hill, Pergam, Cox (bib0082) 2018; 24
Marshall, McCrea, Macha (bib0053) 2018; 58
Bilgrami, Aslanzadeh, Feingold (bib0108) 1999; 24
Nakamura, La Rosa, Longmate (bib0139) 2016; 3
Ljungman, Perez-Bercoff, Jonsson (bib0034) 2006; 91
Lin, Flynn, DeRespiris (bib0059) 2021; 27
El Haddad, Ariza-Heredia, Shah (bib0128) 2019; 219
Hebart, Schroder, Loffler (bib0110) 1997; 175
Navarro, Amat, de la Camara (bib0132) 2016; 3
Boeckh, Corey (bib0149) 2017; 216
Baden, Swaminathan, Angarone (bib0066) 2016; 14
Solano, Gimenez, Pinana (bib0085) 2016; 51
Ciurea, Mulanovich, Saliba (bib0177) 2012; 18
Chakrabarti, Collingham, Osman, Fegan, Milligan (bib0093) 2001; 28
Wang, Freed, He (bib0136) 2016; 8
Salzberger, Bowden, Hackman, Davis, Boeckh (bib0092) 1997; 90
Watanabe, Kanda, Hishizawa, Kondo, Yamashita, Takaori-Kondo (bib0158) 2019; 21
Kropeit, McCormick, Erb-Zohar (bib0048) 2017; 83
Fisher, Boge, Dvorak (bib0076) 2018; 5
Ljungman, Bermudez, Logan (bib0133) 2021; 33
Lin, Maloy, Su (bib0060) 2019; 21
Ratko, Cummings, Oberman (bib0030) 2001; 41
Einsele, Reusser, Bornhauser (bib0091) 2006; 107
Ljungman, Schmitt, Marty (bib0010) 2020; 70
Bontant, Sedlacek, Balduzzi (bib0075) 2014; 49
Sullivan, Goldmuntz, Keyes-Elstein (bib0115) 2018; 378
Micklethwaite, Clancy, Sandher (bib0146) 2008; 112
Lin, Su, Hsu, Wang, Teng (bib0172) 2019; 21
Fries, Riddell, Kim (bib0104) 2005; 11
Egli, Humar, Kumar (bib0125) 2012; 55
Robin, Thiebaut, Alain (bib0064) 2020; 26
Terrier, Zanella, Masouridi-Levrat (bib0054) 2021; 65
Adler, Lewis, Conlon (bib0120) 2019; 220
Peggs, Verfuerth, Pizzey (bib0147) 2003; 362
Kiehl, Basara (bib0094) 2001; 98
Kilgore, Becken, Varga (bib0118) 2020; 9
Cohen, Yeshurun, Shpilberg, Ram (bib0156) 2015; 17
Emery, Griffiths (bib0087) 2000; 97
Boeckh, Nichols, Chemaly (bib0100) 2015; 162
Boeckh, Leisenring, Riddell (bib0103) 2003; 101
Kropeit, von Richter, Stobernack, Rubsamen-Schaeff, Zimmermann (bib0050) 2018; 7
Blyth, Clancy, Simms (bib0143) 2013; 121
Ljungman, de La Camara, Milpied (bib0079) 2002; 99
Takenaka, Nishida, Asano-Mori (bib0014) 2015; 21
Chiereghin, Belotti, Borgatti (bib0117) 2021; 14
Anderson, Raja, Vazquez, Morris, Komanduri, Camargo (bib0056) 2020; 34
Mengarelli, Annibali, Pimpinelli (bib0112) 2016; 72
Bacigalupo, Mordini, Pitto (bib0160) 1997; 98
Ruutu, Ljungman, Brinch (bib0040) 1997; 19
Bregante, Bertilson, Tedone (bib0073) 2000; 26
Raj, Hari, Pasquini (bib0169) 2016; 51
Tey, Kennedy, Cromer (bib0130) 2013; 8
van Rhenen, Gulliksson, Cazenave (bib0032) 2003; 101
Ljungman, Larsson, Kumlien (bib0028) 2002; 34
Busca, de Fabritiis, Ghisetti (bib0089) 2007; 9
Bowden, Fisher, Rogers, Cays, Meyers (bib0039) 1991; 164
Einsele, Hebart, Kauffmann-Schneider (bib0101) 2000; 25
Goodrum, Caviness, Zagallo (bib0004) 2012; 14
Cassaniti, Colombo, Bernasconi (bib0063) 2021; 21
Einsele, Roosnek, Rufer (bib0140) 2002; 99
Mori, Jinnouchi, Takenaka (bib0061) 2021; 56
Holmberg, Boeckh, Hooper (bib0114) 1999; 94
George, Pati, Gilroy (bib0018) 2010; 12
Kropeit, Scheuenpflug, Erb-Zohar (bib0049) 2017; 83
Green, Leisenring, Stachel (bib0007) 2012; 18
Corp MSD. PREVYMIS: Package Insert and Label Information. 2017.
Bowden, Sayers, Flournoy (bib0041) 1986; 314
Fleming, Dunne, Crowley (bib0129) 2010; 82
Plotkin, Boppana (bib0135) 2019; 37
Chakrabarti, Milligan, Brown (bib0162) 2004; 33
Marty, Winston, Chemaly (bib0006) 2019; 25
Yokoyama, Takenaka, Nishida (bib0015) 2020; 26
Peggs, Preiser, Kottaridis (bib0102) 2000; 111
Dowd, Aiello, Alley (bib0020) 2009; 137
Reusser, Gambertoglio, Lilleby, Meyers (bib0074) 1992; 166
Feuchtinger, Opherk, Bethge (bib0141) 2010; 116
Navarro, Fernandez-Ruiz, Aguado, Sandonis, Perez-Romero (bib0019) 2019; 29
Kerkhoffs, van Putten, Novotny (bib0031) 2010; 150
Blajchman, Goldman, Freedman, Sher (bib0026) 2001; 15
Aldoss, La Rosa, Baden (bib0138) 2020; 172
Ozdemir, Saliba, Champlin (bib0035) 2007; 40
Chen, Cheng, Hammond, Einsele, Marty (bib0080) 2018; 2
Duong, Sweet, Jain (bib0052) 2019; 75
Chemaly, Chou, Einsele (bib0097) 2019; 68
Suarez-Lledo, Martinez-Cibrian, Gutierrez-Garcia (bib0157) 2018; 24
Styczynski, Tridello, Xhaard (bib0116) 2021; 56
Ayala, Greene, Sandin (bib0088) 2006; 37
Raiola, Dominietto, di Grazia (bib0168) 2014; 20
Nakamae, Kirby, Sandmaier (bib0022) 2009; 15
Schmidt-Hieber, Labopin, Beelen (bib0150) 2013; 122
Crocchiolo, Castagna, Furst (bib0166) 2016; 51
Ljungman, Brand, Hoek (bib0024) 2014; 59
Derigs, Radujkovic, Schubert (bib0057) 2021; 100
Einsele, Ehninger, Hebart (bib0096) 1995; 86
Leen, Bollard, Mendizabal (bib0148) 2013; 121
Boeckh, Bowden, Gooley, Myerson, Corey (bib0070) 1999; 93
Razonable, Humar (bib0126) 2019; 33
Baker, Wang, Rowley (bib0165) 2016; 22
Micklethwaite, Hansen, Foster (bib0145) 2007; 13
van der Heiden, Kalpoe, Barge, Willemze, Kroes, Schippers (bib0090) 2006; 37
Kim, Goulston, Sanders (bib0111) 2012; 18
Chemaly, El Haddad, Winston (bib0127) 2020; 71
Chou (bib0122) 2015; 59
Muñoz-Cobo, Solano, Costa (bib0086) 2011; 17
Strenger, Sperl, Kubesch (bib0119) 2019; 74
Meyers, Reed, Shepp (bib0077) 1988; 318
Sharma, Gakhar, MacDonald (bib0062) 2020; 55
Yakushiji, Gondo, Kamezaki (bib0046) 2002; 29
Green, Leisenring, Xie (bib0012) 2013; 122
Boeckh, Gallez-Hawkins, Myerson, Zaia, Bowden (bib0042) 1997; 64
Mackinnon, Thomson, Verfuerth, Peggs, Lowdell (bib0144) 2008; 40
Schmidt-Hieber, Schwarck, Stroux (bib0164) 2010; 91
Ramanathan, Teira, Battiwalla (bib0013) 2016; 51
Nitsche, Oswald, Steuer (bib0045) 2003; 49
Teira, Battiwalla, Ramanathan (bib0009) 2016; 127
Bacigalupo, Tedone, Van Lint (bib0072) 1994; 13
Winston, Yeager, Chandrasekar, Snydman, Petersen, Territo (bib0067) 2003; 36
Zamora, Duke, Xie (bib0065) 2021; 138
Marty, Ljungman, Chemaly (bib0005) 2017; 377
Pergam, Xie, Sandhu (bib0023) 2012; 18
Kollman, Spellman, Zhang (bib0037) 2016; 127
Fowler, Ross, Shimamura (bib0021) 2018; 200
Carpenter, Papanicolaou, Chemaly, Boeckh, Savani (bib0002) 2021; 27
Matsuda, Hara, Osugi (bib0163) 1998; 21
Kline, Pollyea, Stock (bib0107) 2006; 37
Gimeno, Solano, Latorre (bib0043) 2008; 46
Elmaagacli, Koldehoff (bib0011) 2016; 128
Nichols, Corey, Gooley, Davis, Boeckh (bib0025) 2002; 185
Mikulska, Raiola, Bruzzi (bib0036) 2012; 18
Rossini, Terruzzi, Cammarota (bib0113) 2005; 7
Ljungman, Aschan, Lewensohn-Fuchs (bib0151) 1998; 66
Ljungman, Deliliers, Platzbecker (bib0095) 2001; 97
Johnsrud, Nguyen, Domingo, Narasimhan, Efron, Brown (bib0058) 2020; 26
Maertens, Cordonnier, Jaksch (bib0121) 2019; 381
Chakrabarti, Mackinnon, Chopra (bib0161) 2002; 99
George, Kerridge, Gilroy (bib0153) 2012; 14
Servais, Dumontier, Biard (bib0099) 2016; 22
Slade, Goldsmith, Romee (bib0170) 2017; 19
Pirofski, Casadevall (bib0001) 2018; 218
Hammerstrom, Lombardi, Pingali (bib0105) 2018; 24
Osarogiagbon, Defor, Weisdorf, Erice, Weisdorf (bib0152) 2000; 6
Avetisyan, Aschan, Hagglund, Ringden, Ljungman (bib0131) 2007; 40
Green, Leisenring, Xie (bib0008) 2016; 3
Allen, Marsh, Dawson (bib0083) 2018; 132
Yoon, Lee, Choi (bib0154) 2009; 13
Bowden, Cays, Schoch (bib0027) 1995; 86
McCrea, Macha, Adedoyin (bib0051) 2019; 59
Milano, Pergam, Xie (bib0081) 2011; 118
Goldsmith, Abid, Auletta (bib0016) 2021; 137
Meesing, Abraham, Razonable (bib0174) 2019; 103
Robin, Hemery, Dindorf (bib0098) 2017; 17
Douglas, Barnard, Holder (bib0124) 2020; 221
Guilcher, Truong, Saraf, Joseph, Rondelli, Hsieh (bib0084) 2018; 55
Pei, Zhao, Chang (bib0142) 2017; 216
Shaw, Logan, Spellman (bib0038) 2018; 24
Winston, Ho, Bartoni (bib0069) 1993; 118
Reusser, Einsele, Lee (bib0047) 2002; 99
Prentice, Gluckman, Powles (bib0078) 1994; 343
Bowden (10.1016/j.jtct.2021.05.001_bib0041) 1986; 314
Micklethwaite (10.1016/j.jtct.2021.05.001_bib0146) 2008; 112
Mikulska (10.1016/j.jtct.2021.05.001_bib0036) 2012; 18
Kropeit (10.1016/j.jtct.2021.05.001_bib0048) 2017; 83
Chakrabarti (10.1016/j.jtct.2021.05.001_bib0093) 2001; 28
McCrea (10.1016/j.jtct.2021.05.001_bib0051) 2019; 59
Ljungman (10.1016/j.jtct.2021.05.001_bib0003) 2017; 64
Shaw (10.1016/j.jtct.2021.05.001_bib0038) 2018; 24
Aldoss (10.1016/j.jtct.2021.05.001_bib0138) 2020; 172
Raj (10.1016/j.jtct.2021.05.001_bib0169) 2016; 51
Bacigalupo (10.1016/j.jtct.2021.05.001_bib0072) 1994; 13
Nichols (10.1016/j.jtct.2021.05.001_bib0029) 2003; 101
Blajchman (10.1016/j.jtct.2021.05.001_bib0026) 2001; 15
Reusser (10.1016/j.jtct.2021.05.001_bib0074) 1992; 166
Hill (10.1016/j.jtct.2021.05.001_bib0082) 2018; 24
Duong (10.1016/j.jtct.2021.05.001_bib0052) 2019; 75
Meyers (10.1016/j.jtct.2021.05.001_bib0077) 1988; 318
10.1016/j.jtct.2021.05.001_bib0055
Sharma (10.1016/j.jtct.2021.05.001_bib0062) 2020; 55
Schmidt-Hieber (10.1016/j.jtct.2021.05.001_bib0150) 2013; 122
Salzberger (10.1016/j.jtct.2021.05.001_bib0092) 1997; 90
Kiehl (10.1016/j.jtct.2021.05.001_bib0094) 2001; 98
Han (10.1016/j.jtct.2021.05.001_bib0176) 2007; 45
Bacigalupo (10.1016/j.jtct.2021.05.001_bib0160) 1997; 98
Ljungman (10.1016/j.jtct.2021.05.001_bib0010) 2020; 70
Peggs (10.1016/j.jtct.2021.05.001_bib0102) 2000; 111
Marty (10.1016/j.jtct.2021.05.001_bib0006) 2019; 25
Kilgore (10.1016/j.jtct.2021.05.001_bib0118) 2020; 9
Baden (10.1016/j.jtct.2021.05.001_bib0066) 2016; 14
Einsele (10.1016/j.jtct.2021.05.001_bib0091) 2006; 107
Verma (10.1016/j.jtct.2021.05.001_bib0106) 2003; 31
Zhou (10.1016/j.jtct.2021.05.001_bib0033) 2009; 113
Liu (10.1016/j.jtct.2021.05.001_bib0134) 2019; 93
Feuchtinger (10.1016/j.jtct.2021.05.001_bib0141) 2010; 116
Boeckh (10.1016/j.jtct.2021.05.001_bib0109) 1996; 174
Ljungman (10.1016/j.jtct.2021.05.001_bib0079) 2002; 99
Nitsche (10.1016/j.jtct.2021.05.001_bib0045) 2003; 49
Kim (10.1016/j.jtct.2021.05.001_bib0111) 2012; 18
Bilgrami (10.1016/j.jtct.2021.05.001_bib0108) 1999; 24
Servais (10.1016/j.jtct.2021.05.001_bib0099) 2016; 22
Suarez-Lledo (10.1016/j.jtct.2021.05.001_bib0157) 2018; 24
Anderson (10.1016/j.jtct.2021.05.001_bib0056) 2020; 34
Mori (10.1016/j.jtct.2021.05.001_bib0061) 2021; 56
Takenaka (10.1016/j.jtct.2021.05.001_bib0014) 2015; 21
Goodrum (10.1016/j.jtct.2021.05.001_bib0004) 2012; 14
Lin (10.1016/j.jtct.2021.05.001_bib0060) 2019; 21
Goodrich (10.1016/j.jtct.2021.05.001_bib0068) 1993; 118
Ciurea (10.1016/j.jtct.2021.05.001_bib0177) 2012; 18
Boeckh (10.1016/j.jtct.2021.05.001_bib0178) 1996; 88
Muñoz-Cobo (10.1016/j.jtct.2021.05.001_bib0086) 2011; 17
George (10.1016/j.jtct.2021.05.001_bib0153) 2012; 14
Chen (10.1016/j.jtct.2021.05.001_bib0080) 2018; 2
Solano (10.1016/j.jtct.2021.05.001_bib0085) 2016; 51
Boeckh (10.1016/j.jtct.2021.05.001_bib0070) 1999; 93
Plotkin (10.1016/j.jtct.2021.05.001_bib0135) 2019; 37
Fries (10.1016/j.jtct.2021.05.001_bib0104) 2005; 11
Baker (10.1016/j.jtct.2021.05.001_bib0165) 2016; 22
Goldsmith (10.1016/j.jtct.2021.05.001_bib0016) 2021; 137
Green (10.1016/j.jtct.2021.05.001_bib0008) 2016; 3
Winston (10.1016/j.jtct.2021.05.001_bib0067) 2003; 36
Boeckh (10.1016/j.jtct.2021.05.001_bib0103) 2003; 101
Ljungman (10.1016/j.jtct.2021.05.001_bib0024) 2014; 59
Osarogiagbon (10.1016/j.jtct.2021.05.001_bib0152) 2000; 6
Yokoyama (10.1016/j.jtct.2021.05.001_bib0015) 2020; 26
Milano (10.1016/j.jtct.2021.05.001_bib0081) 2011; 118
Dowd (10.1016/j.jtct.2021.05.001_bib0020) 2009; 137
Ratko (10.1016/j.jtct.2021.05.001_bib0030) 2001; 41
Meesing (10.1016/j.jtct.2021.05.001_bib0174) 2019; 103
Miller (10.1016/j.jtct.2021.05.001_bib0155) 1986; 67
Adler (10.1016/j.jtct.2021.05.001_bib0120) 2019; 220
Green (10.1016/j.jtct.2021.05.001_bib0012) 2013; 122
Peggs (10.1016/j.jtct.2021.05.001_bib0147) 2003; 362
Einsele (10.1016/j.jtct.2021.05.001_bib0101) 2000; 25
Fowler (10.1016/j.jtct.2021.05.001_bib0021) 2018; 200
Johnsrud (10.1016/j.jtct.2021.05.001_bib0058) 2020; 26
Pirofski (10.1016/j.jtct.2021.05.001_bib0001) 2018; 218
Kollman (10.1016/j.jtct.2021.05.001_bib0037) 2016; 127
Matsuda (10.1016/j.jtct.2021.05.001_bib0163) 1998; 21
Sullivan (10.1016/j.jtct.2021.05.001_bib0115) 2018; 378
Teira (10.1016/j.jtct.2021.05.001_bib0009) 2016; 127
Robin (10.1016/j.jtct.2021.05.001_bib0064) 2020; 26
Douglas (10.1016/j.jtct.2021.05.001_bib0124) 2020; 221
Marshall (10.1016/j.jtct.2021.05.001_bib0053) 2018; 58
Kerkhoffs (10.1016/j.jtct.2021.05.001_bib0031) 2010; 150
Ljungman (10.1016/j.jtct.2021.05.001_bib0028) 2002; 34
Ljungman (10.1016/j.jtct.2021.05.001_bib0151) 1998; 66
Navarro (10.1016/j.jtct.2021.05.001_bib0019) 2019; 29
Aversa (10.1016/j.jtct.2021.05.001_bib0159) 2005; 23
Bowden (10.1016/j.jtct.2021.05.001_bib0039) 1991; 164
Holmberg (10.1016/j.jtct.2021.05.001_bib0114) 1999; 94
Fisher (10.1016/j.jtct.2021.05.001_bib0076) 2018; 5
Ljungman (10.1016/j.jtct.2021.05.001_bib0133) 2021; 33
Cassaniti (10.1016/j.jtct.2021.05.001_bib0063) 2021; 21
Boeckh (10.1016/j.jtct.2021.05.001_bib0149) 2017; 216
Busca (10.1016/j.jtct.2021.05.001_bib0089) 2007; 9
Ksouri (10.1016/j.jtct.2021.05.001_bib0044) 2007; 9
Kropeit (10.1016/j.jtct.2021.05.001_bib0050) 2018; 7
Pergam (10.1016/j.jtct.2021.05.001_bib0023) 2012; 18
Goldsmith (10.1016/j.jtct.2021.05.001_bib0167) 2016; 101
George (10.1016/j.jtct.2021.05.001_bib0018) 2010; 12
Robin (10.1016/j.jtct.2021.05.001_bib0098) 2017; 17
Cohen (10.1016/j.jtct.2021.05.001_bib0156) 2015; 17
Yakushiji (10.1016/j.jtct.2021.05.001_bib0046) 2002; 29
Chemaly (10.1016/j.jtct.2021.05.001_bib0097) 2019; 68
Reusser (10.1016/j.jtct.2021.05.001_bib0047) 2002; 99
Yoon (10.1016/j.jtct.2021.05.001_bib0154) 2009; 13
Strenger (10.1016/j.jtct.2021.05.001_bib0119) 2019; 74
Fleming (10.1016/j.jtct.2021.05.001_bib0129) 2010; 82
Winston (10.1016/j.jtct.2021.05.001_bib0069) 1993; 118
Lin (10.1016/j.jtct.2021.05.001_bib0172) 2019; 21
Rossini (10.1016/j.jtct.2021.05.001_bib0113) 2005; 7
Lin (10.1016/j.jtct.2021.05.001_bib0059) 2021; 27
Terrier (10.1016/j.jtct.2021.05.001_bib0054) 2021; 65
Pollack (10.1016/j.jtct.2021.05.001_bib0071) 2011; 17
Marty (10.1016/j.jtct.2021.05.001_bib0005) 2017; 377
Gimeno (10.1016/j.jtct.2021.05.001_bib0043) 2008; 46
Einsele (10.1016/j.jtct.2021.05.001_bib0175) 1993; 82
Ayala (10.1016/j.jtct.2021.05.001_bib0088) 2006; 37
Tischer (10.1016/j.jtct.2021.05.001_bib0171) 2015; 94
Mackinnon (10.1016/j.jtct.2021.05.001_bib0144) 2008; 40
Chiereghin (10.1016/j.jtct.2021.05.001_bib0117) 2021; 14
Walker (10.1016/j.jtct.2021.05.001_bib0173) 2007; 13
Derigs (10.1016/j.jtct.2021.05.001_bib0057) 2021; 100
Bregante (10.1016/j.jtct.2021.05.001_bib0073) 2000; 26
Tey (10.1016/j.jtct.2021.05.001_bib0130) 2013; 8
Hammerstrom (10.1016/j.jtct.2021.05.001_bib0105) 2018; 24
Blyth (10.1016/j.jtct.2021.05.001_bib0143) 2013; 121
Chakrabarti (10.1016/j.jtct.2021.05.001_bib0162) 2004; 33
Egli (10.1016/j.jtct.2021.05.001_bib0125) 2012; 55
Ozdemir (10.1016/j.jtct.2021.05.001_bib0035) 2007; 40
Chakrabarti (10.1016/j.jtct.2021.05.001_bib0161) 2002; 99
Ljungman (10.1016/j.jtct.2021.05.001_bib0095) 2001; 97
Watanabe (10.1016/j.jtct.2021.05.001_bib0158) 2019; 21
Einsele (10.1016/j.jtct.2021.05.001_bib0096) 1995; 86
Crocchiolo (10.1016/j.jtct.2021.05.001_bib0166) 2016; 51
Guilcher (10.1016/j.jtct.2021.05.001_bib0084) 2018; 55
Chou (10.1016/j.jtct.2021.05.001_bib0122) 2015; 59
Green (10.1016/j.jtct.2021.05.001_bib0007) 2012; 18
Bowden (10.1016/j.jtct.2021.05.001_bib0027) 1995; 86
Bontant (10.1016/j.jtct.2021.05.001_bib0075) 2014; 49
Micklethwaite (10.1016/j.jtct.2021.05.001_bib0145) 2007; 13
Nakamae (10.1016/j.jtct.2021.05.001_bib0022) 2009; 15
El Haddad (10.1016/j.jtct.2021.05.001_bib0128) 2019; 219
Diamond (10.1016/j.jtct.2021.05.001_bib0137) 2018; 17
Zamora (10.1016/j.jtct.2021.05.001_bib0065) 2021; 138
Chemaly (10.1016/j.jtct.2021.05.001_bib0127) 2020; 71
Kline (10.1016/j.jtct.2021.05.001_bib0107) 2006; 37
Lindsay (10.1016/j.jtct.2021.05.001_bib0017) 2021; 23
Prentice (10.1016/j.jtct.2021.05.001_bib0078) 1994; 343
Slade (10.1016/j.jtct.2021.05.001_bib0170) 2017; 19
Marty (10.1016/j.jtct.2021.05.001_bib0123) 2020; 20
Nakamura (10.1016/j.jtct.2021.05.001_bib0139) 2016; 3
Hebart (10.1016/j.jtct.2021.05.001_bib0110) 1997; 175
Schmidt-Hieber (10.1016/j.jtct.2021.05.001_bib0164) 2010; 91
Styczynski (10.1016/j.jtct.2021.05.001_bib0116) 2021; 56
Leen (10.1016/j.jtct.2021.05.001_bib0148) 2013; 121
Navarro (10.1016/j.jtct.2021.05.001_bib0132) 2016; 3
Elmaagacli (10.1016/j.jtct.2021.05.001_bib0011) 2016; 128
Ruutu (10.1016/j.jtct.2021.05.001_bib0040) 1997; 19
Razonable (10.1016/j.jtct.2021.05.001_bib0126) 2019; 33
Carpenter (10.1016/j.jtct.2021.05.001_bib0002) 2021; 27
Wang (10.1016/j.jtct.2021.05.001_bib0136) 2016; 8
Kropeit (10.1016/j.jtct.2021.05.001_bib0049) 2017; 83
Nichols (10.1016/j.jtct.2021.05.001_bib0025) 2002; 185
Pei (10.1016/j.jtct.2021.05.001_bib0142) 2017; 216
van der Heiden (10.1016/j.jtct.2021.05.001_bib0090) 2006; 37
Mengarelli (10.1016/j.jtct.2021.05.001_bib0112) 2016; 72
Raiola (10.1016/j.jtct.2021.05.001_bib0168) 2014; 20
Emery (10.1016/j.jtct.2021.05.001_bib0087) 2000; 97
Avetisyan (10.1016/j.jtct.2021.05.001_bib0131) 2007; 40
Boeckh (10.1016/j.jtct.2021.05.001_bib0100) 2015; 162
Boeckh (10.1016/j.jtct.2021.05.001_bib0042) 1997; 64
Maertens (10.1016/j.jtct.2021.05.001_bib0121) 2019; 381
Ramanathan (10.1016/j.jtct.2021.05.001_bib0013) 2016; 51
Allen (10.1016/j.jtct.2021.05.001_bib0083) 2018; 132
Einsele (10.1016/j.jtct.2021.05.001_bib0140) 2002; 99
van Rhenen (10.1016/j.jtct.2021.05.001_bib0032) 2003; 101
Ljungman (10.1016/j.jtct.2021.05.001_bib0034) 2006; 91
References_xml – volume: 9
  start-page: 16
  year: 2007
  end-page: 21
  ident: bib0044
  article-title: Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation
  publication-title: Transpl Infect Dis
– volume: 174
  start-page: 907
  year: 1996
  end-page: 912
  ident: bib0109
  article-title: Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation
  publication-title: J Infect Dis
– volume: 72
  start-page: 265
  year: 2016
  end-page: 268
  ident: bib0112
  article-title: Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant
  publication-title: J Infect
– volume: 66
  start-page: 1330
  year: 1998
  end-page: 1334
  ident: bib0151
  article-title: Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
  publication-title: Transplantation
– volume: 24
  start-page: 2094
  year: 2018
  end-page: 2100
  ident: bib0082
  article-title: A modified intensive strategy to prevent cytomegalovirus disease in seropositive umbilical cord blood transplantation recipients
  publication-title: Biol Blood Marrow Transplant
– volume: 8
  year: 2016
  ident: bib0136
  article-title: A replication-defective human cytomegalovirus vaccine for prevention of congenital infection
  publication-title: Sci Transl Med
– volume: 55
  start-page: 87
  year: 2018
  end-page: 93
  ident: bib0084
  article-title: Curative therapies: allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease
  publication-title: Semin Hematol
– volume: 99
  start-page: 3916
  year: 2002
  end-page: 3922
  ident: bib0140
  article-title: Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy
  publication-title: Blood
– volume: 13
  start-page: 1106
  year: 2007
  end-page: 1115
  ident: bib0173
  article-title: Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources
  publication-title: Biol Blood Marrow Transplant
– volume: 9
  start-page: 102
  year: 2007
  end-page: 107
  ident: bib0089
  article-title: Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation
  publication-title: Transpl Infect Dis
– volume: 175
  start-page: 1490
  year: 1997
  end-page: 1493
  ident: bib0110
  article-title: Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation
  publication-title: J Infect Dis
– volume: 93
  year: 2019
  ident: bib0134
  article-title: A replication-defective human cytomegalovirus vaccine elicits humoral immune responses analogous to those with natural infection
  publication-title: J Virol
– volume: 37
  start-page: 307
  year: 2006
  end-page: 310
  ident: bib0107
  article-title: Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning
  publication-title: Bone Marrow Transplant
– volume: 164
  start-page: 483
  year: 1991
  end-page: 487
  ident: bib0039
  article-title: Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant
  publication-title: J Infect Dis
– volume: 65
  year: 2021
  ident: bib0054
  article-title: Concomitant administration of posaconazole and isavuconazole with letermovir: clinical and pharmacological considerations
  publication-title: Antimicrob Agents Chemother
– volume: 59
  start-page: 6588
  year: 2015
  end-page: 6593
  ident: bib0122
  article-title: Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance
  publication-title: Antimicrob Agents Chemother
– volume: 31
  start-page: 813
  year: 2003
  end-page: 816
  ident: bib0106
  article-title: Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir
  publication-title: Bone Marrow Transplant
– volume: 7
  start-page: 122
  year: 2005
  end-page: 125
  ident: bib0113
  article-title: Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program
  publication-title: Transpl Infect Dis
– volume: 11
  start-page: 136
  year: 2005
  end-page: 148
  ident: bib0104
  article-title: Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation
  publication-title: Biol Blood Marrow Transplant
– volume: 97
  start-page: 8039
  year: 2000
  end-page: 8044
  ident: bib0087
  article-title: Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy
  publication-title: Proc Natl Acad Sci U S A
– volume: 172
  start-page: 306
  year: 2020
  end-page: 316
  ident: bib0138
  article-title: Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial
  publication-title: Ann Intern Med
– volume: 88
  start-page: 4063
  year: 1996
  end-page: 4071
  ident: bib0178
  article-title: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study
  publication-title: Blood
– volume: 64
  start-page: 87
  year: 2017
  end-page: 91
  ident: bib0003
  article-title: Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials
  publication-title: Clin Infect Dis
– volume: 121
  start-page: 5113
  year: 2013
  end-page: 5123
  ident: bib0148
  article-title: Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
  publication-title: Blood
– volume: 17
  start-page: 747
  year: 2017
  ident: bib0098
  article-title: Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients
  publication-title: BMC Infect Dis
– volume: 378
  start-page: 35
  year: 2018
  end-page: 47
  ident: bib0115
  article-title: Myeloablative autologous stem-cell transplantation for severe scleroderma
  publication-title: N Engl J Med
– volume: 83
  start-page: 1944
  year: 2017
  end-page: 1953
  ident: bib0049
  article-title: Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment
  publication-title: Br J Clin Pharmacol
– volume: 40
  start-page: 125
  year: 2007
  end-page: 136
  ident: bib0035
  article-title: Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies
  publication-title: Bone Marrow Transplant
– volume: 36
  start-page: 749
  year: 2003
  end-page: 758
  ident: bib0067
  article-title: Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation
  publication-title: Clin Infect Dis
– volume: 56
  start-page: 1171
  year: 2021
  end-page: 1179
  ident: bib0116
  article-title: Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study
  publication-title: Bone Marrow Transplant
– volume: 71
  start-page: 2365
  year: 2020
  end-page: 2374
  ident: bib0127
  article-title: Cytomegalovirus (CMV) cell-mediated immunity and cmv infection after allogeneic hematopoietic cell transplantation: the REACT Study
  publication-title: Clin Infect Dis
– volume: 127
  start-page: 260
  year: 2016
  end-page: 267
  ident: bib0037
  article-title: The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy
  publication-title: Blood
– volume: 21
  start-page: e13096
  year: 2019
  ident: bib0172
  article-title: Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia
  publication-title: Transpl Infect Dis
– volume: 128
  start-page: 456
  year: 2016
  end-page: 459
  ident: bib0011
  article-title: Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia
  publication-title: Blood
– volume: 82
  year: 1993
  ident: bib0175
  article-title: Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation
  publication-title: Blood
– volume: 216
  start-page: 945
  year: 2017
  end-page: 956
  ident: bib0142
  article-title: Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus
  publication-title: J Infect Dis
– volume: 59
  start-page: 1331
  year: 2019
  end-page: 1339
  ident: bib0051
  article-title: Pharmacokinetic drug-drug interactions between letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil
  publication-title: J Clin Pharmacol
– volume: 21
  start-page: 2008
  year: 2015
  end-page: 2016
  ident: bib0014
  article-title: Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group
  publication-title: Biol Blood Marrow Transplant
– volume: 113
  start-page: 6465
  year: 2009
  end-page: 6476
  ident: bib0033
  article-title: Impact of donor CMV-status on viral infection and reconstitution of multi-function CMV-specific T-cells in CMV-positive transplant recipients
  publication-title: Blood
– volume: 5
  year: 2018
  ident: bib0076
  article-title: A survey of pediatric bone marrow transplant centers regarding local cytomegalovirus prophylaxis management practices and interest in a future randomized trial
  publication-title: ID Week Vol
– volume: 40
  start-page: 865
  year: 2007
  end-page: 869
  ident: bib0131
  article-title: Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT
  publication-title: Bone Marrow Transplant
– volume: 21
  start-page: 355
  year: 1998
  end-page: 360
  ident: bib0163
  article-title: Allogeneic peripheral stem cell transplantation using positively selected CD34+ cells from HLA-mismatched donors
  publication-title: Bone Marrow Transplant
– volume: 3
  start-page: e87
  year: 2016
  end-page: e98
  ident: bib0139
  article-title: Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial
  publication-title: Lancet Haematol
– volume: 101
  start-page: 2426
  year: 2003
  end-page: 2433
  ident: bib0032
  article-title: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial
  publication-title: Blood
– volume: 14
  start-page: 1185
  year: 2021
  end-page: 1190
  ident: bib0117
  article-title: Off-label use of letermovir as preemptive anti-cytomegalovirus therapy in a pediatric allogeneic peripheral blood stem cell transplant
  publication-title: Infect Drug Resist
– volume: 377
  start-page: 2433
  year: 2017
  end-page: 2444
  ident: bib0005
  article-title: Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
  publication-title: N Engl J Med
– volume: 94
  start-page: 4029
  year: 1999
  end-page: 4035
  ident: bib0114
  article-title: Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation
  publication-title: Blood
– volume: 23
  start-page: 3447
  year: 2005
  end-page: 3454
  ident: bib0159
  article-title: Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse
  publication-title: J Clin Oncol
– volume: 93
  start-page: 1781
  year: 1999
  end-page: 1782
  ident: bib0070
  article-title: Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
  publication-title: Blood
– volume: 166
  start-page: 473
  year: 1992
  end-page: 479
  ident: bib0074
  article-title: Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients
  publication-title: J Infect Dis
– volume: 56
  start-page: 853
  year: 2021
  end-page: 862
  ident: bib0061
  article-title: Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data
  publication-title: Bone Marrow Transplant
– volume: 24
  start-page: 353
  year: 2018
  end-page: 358
  ident: bib0105
  article-title: Prevention of cytomegalovirus reactivation in haploidentical stem cell transplantation
  publication-title: Biol Blood Marrow Transplant
– volume: 99
  start-page: 4357
  year: 2002
  end-page: 4363
  ident: bib0161
  article-title: High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
  publication-title: Blood
– volume: 116
  start-page: 4360
  year: 2010
  end-page: 4367
  ident: bib0141
  article-title: Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation
  publication-title: Blood
– volume: 343
  start-page: 749
  year: 1994
  end-page: 753
  ident: bib0078
  article-title: Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group
  publication-title: Lancet
– volume: 24
  start-page: 69
  year: 1999
  end-page: 73
  ident: bib0108
  article-title: Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance
  publication-title: Bone Marrow Transplant
– volume: 118
  start-page: 5689
  year: 2011
  end-page: 5696
  ident: bib0081
  article-title: Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients
  publication-title: Blood
– volume: 18
  start-page: 1835
  year: 2012
  end-page: 1844
  ident: bib0177
  article-title: Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation
  publication-title: Biol Blood Marrow Transplant
– volume: 46
  start-page: 3311
  year: 2008
  end-page: 3318
  ident: bib0043
  article-title: Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients
  publication-title: J Clin Microbiol
– volume: 7
  start-page: 9
  year: 2018
  end-page: 21
  ident: bib0050
  article-title: Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects
  publication-title: Clin Pharmacol Drug Dev
– volume: 318
  start-page: 70
  year: 1988
  end-page: 75
  ident: bib0077
  article-title: Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
  publication-title: N Engl J Med
– volume: 33
  year: 2021
  ident: bib0133
  article-title: A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients
  publication-title: EClinicalMedicine
– volume: 103
  start-page: 832
  year: 2019
  end-page: 838
  ident: bib0174
  article-title: Clinical correlation of cytomegalovirus infection with CMV-specific CD8+ T-cell immune competence score and lymphocyte subsets in solid organ transplant recipients
  publication-title: Transplantation
– volume: 14
  start-page: 141
  year: 2012
  end-page: 148
  ident: bib0153
  article-title: A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group
  publication-title: Transpl Infect Dis
– volume: 37
  start-page: 693
  year: 2006
  end-page: 698
  ident: bib0090
  article-title: Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients
  publication-title: Bone Marrow Transplant
– volume: 51
  start-page: 718
  year: 2016
  end-page: 721
  ident: bib0085
  article-title: Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood
  publication-title: Bone Marrow Transplant
– volume: 13
  start-page: 783
  year: 1994
  end-page: 788
  ident: bib0072
  article-title: CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections
  publication-title: Bone Marrow Transplant
– volume: 98
  start-page: 760
  year: 1997
  end-page: 766
  ident: bib0160
  article-title: Transplantation of HLA-mismatched CD34+ selected cells in patients with advanced malignancies: severe immunodeficiency and related complications
  publication-title: Br J Haematol
– volume: 20
  start-page: 1573
  year: 2014
  end-page: 1579
  ident: bib0168
  article-title: Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts
  publication-title: Biol Blood Marrow Transplant
– volume: 3
  start-page: e119
  year: 2016
  end-page: e127
  ident: bib0008
  article-title: Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study
  publication-title: Lancet Haematol
– volume: 127
  start-page: 2427
  year: 2016
  end-page: 2438
  ident: bib0009
  article-title: Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
  publication-title: Blood
– volume: 23
  start-page: e13548
  year: 2021
  ident: bib0017
  article-title: Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance
  publication-title: Transpl Infect Dis
– volume: 18
  start-page: 1391
  year: 2012
  end-page: 1400
  ident: bib0023
  article-title: Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients
  publication-title: Biol Blood Marrow Transplant
– volume: 26
  start-page: 978
  year: 2020
  end-page: 984
  ident: bib0064
  article-title: Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French Compassionate Program
  publication-title: Biol Blood Marrow Transplant
– volume: 14
  start-page: 882
  year: 2016
  end-page: 913
  ident: bib0066
  article-title: Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology
  publication-title: J Natl Compr Canc Netw
– volume: 49
  start-page: 1683
  year: 2003
  end-page: 1685
  ident: bib0045
  article-title: Quantitative real-time PCR compared with pp65 antigen detection for cytomegalovirus (CMV) in 1122 blood specimens from 77 patients after allogeneic stem cell transplantation: which test better predicts CMV disease development?
  publication-title: Clin Chem
– volume: 34
  start-page: e13866
  year: 2020
  ident: bib0056
  article-title: Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients
  publication-title: Clin Transplant
– volume: 68
  start-page: 1420
  year: 2019
  end-page: 1426
  ident: bib0097
  article-title: Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials
  publication-title: Clin Infect Dis
– volume: 18
  start-page: 1687
  year: 2012
  end-page: 1699
  ident: bib0007
  article-title: Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation
  publication-title: Biol Blood Marrow Transplant
– volume: 122
  start-page: 1316
  year: 2013
  end-page: 1324
  ident: bib0012
  article-title: CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia
  publication-title: Blood
– volume: 99
  start-page: 3050
  year: 2002
  end-page: 3056
  ident: bib0079
  article-title: Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants
  publication-title: Blood
– volume: 21
  start-page: e13049
  year: 2019
  ident: bib0158
  article-title: Impact of cumulative steroid dose on infectious diseases after allogenic hematopoietic stem cell transplantation
  publication-title: Transpl Infect Dis
– volume: 90
  start-page: 2502
  year: 1997
  end-page: 2508
  ident: bib0092
  article-title: Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome
  publication-title: Blood
– volume: 101
  start-page: 4195
  year: 2003
  end-page: 4200
  ident: bib0029
  article-title: Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products
  publication-title: Blood
– volume: 29
  start-page: e2017
  year: 2019
  ident: bib0019
  article-title: Going beyond serology for stratifying the risk of CMV infection in transplant recipients
  publication-title: Rev Med Virol
– volume: 49
  start-page: 276
  year: 2014
  end-page: 279
  ident: bib0075
  article-title: Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT
  publication-title: Bone Marrow Transplant
– volume: 6
  start-page: 280
  year: 2000
  end-page: 288
  ident: bib0152
  article-title: CMV antigenemia following bone marrow transplantation: risk factors and outcomes
  publication-title: Biol Blood Marrow Transplant
– volume: 362
  start-page: 1375
  year: 2003
  end-page: 1377
  ident: bib0147
  article-title: Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines
  publication-title: Lancet
– volume: 137
  start-page: 58
  year: 2009
  end-page: 65
  ident: bib0020
  article-title: Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III
  publication-title: Epidemiol Infect
– volume: 15
  start-page: 694
  year: 2009
  end-page: 703
  ident: bib0022
  article-title: Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation
  publication-title: Biol Blood Marrow Transplant
– volume: 74
  start-page: 2820
  year: 2019
  end-page: 2821
  ident: bib0119
  article-title: Letermovir in paediatric HSCT recipients
  publication-title: J Antimicrob Chemother
– volume: 55
  start-page: 780
  year: 2020
  end-page: 786
  ident: bib0062
  article-title: Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation
  publication-title: Bone Marrow Transplant
– volume: 34
  start-page: 347
  year: 2002
  end-page: 350
  ident: bib0028
  article-title: Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors
  publication-title: Scand J Infect Dis
– volume: 101
  start-page: 407
  year: 2003
  end-page: 414
  ident: bib0103
  article-title: Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity
  publication-title: Blood
– volume: 18
  start-page: 92
  year: 2012
  end-page: 99
  ident: bib0036
  article-title: CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus
  publication-title: Biol Blood Marrow Transplant
– volume: 51
  start-page: 1602
  year: 2016
  end-page: 1604
  ident: bib0169
  article-title: Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections
  publication-title: Bone Marrow Transplant
– volume: 381
  start-page: 1136
  year: 2019
  end-page: 1147
  ident: bib0121
  article-title: Maribavir for preemptive treatment of cytomegalovirus reactivation
  publication-title: N Engl J Med
– volume: 91
  start-page: 78
  year: 2006
  end-page: 83
  ident: bib0034
  article-title: Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation
  publication-title: Haematologica
– volume: 75
  start-page: 775
  year: 2019
  end-page: 777
  ident: bib0052
  article-title: Clinically significant drug interaction: letermovir and voriconazole
  publication-title: J Antimicrob Chemother
– volume: 13
  start-page: 707
  year: 2007
  end-page: 714
  ident: bib0145
  article-title: Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation
  publication-title: Biol Blood Marrow Transplant
– volume: 8
  start-page: e74744
  year: 2013
  ident: bib0130
  article-title: Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications
  publication-title: PLoS One
– volume: 67
  start-page: 1162
  year: 1986
  end-page: 1167
  ident: bib0155
  article-title: Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease
  publication-title: Blood
– volume: 29
  start-page: 599
  year: 2002
  end-page: 606
  ident: bib0046
  article-title: Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction
  publication-title: Bone Marrow Transplant
– volume: 86
  start-page: 2815
  year: 1995
  end-page: 2820
  ident: bib0096
  article-title: Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
  publication-title: Blood
– volume: 12
  start-page: 322
  year: 2010
  end-page: 329
  ident: bib0018
  article-title: Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy
  publication-title: Transpl Infect Dis
– volume: 15
  start-page: 1
  year: 2001
  end-page: 20
  ident: bib0026
  article-title: Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction
  publication-title: Transfus Med Rev
– volume: 97
  start-page: 388
  year: 2001
  end-page: 392
  ident: bib0095
  article-title: Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
  publication-title: Blood
– volume: 86
  start-page: 3598
  year: 1995
  end-page: 3603
  ident: bib0027
  article-title: Comparison of filtered blood (FB) to seronegative blood products (SB) for prevention of cytomegalovirus (CMV) infection after marrow transplant
  publication-title: Blood
– volume: 58
  start-page: 897
  year: 2018
  end-page: 904
  ident: bib0053
  article-title: Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects
  publication-title: J Clin Pharmacol
– volume: 218
  start-page: S7
  year: 2018
  end-page: S11
  ident: bib0001
  article-title: The damage-response framework as a tool for the physician-scientist to understand the pathogenesis of infectious diseases
  publication-title: J Infect Dis
– volume: 26
  start-page: 1363
  year: 2020
  end-page: 1370
  ident: bib0015
  article-title: Favorable effect of cytomegalovirus reactivation on outcomes in cord blood transplant and its differences among disease risk or type
  publication-title: Biol Blood Marrow Transplant
– volume: 20
  start-page: 1703
  year: 2020
  end-page: 1711
  ident: bib0123
  article-title: Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation
  publication-title: Am J Transplant
– volume: 37
  start-page: 851
  year: 2006
  end-page: 856
  ident: bib0088
  article-title: Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation
  publication-title: Bone Marrow Transplant
– volume: 221
  start-page: 1117
  year: 2020
  end-page: 1126
  ident: bib0124
  article-title: Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients
  publication-title: J Infect Dis
– volume: 121
  start-page: 3745
  year: 2013
  end-page: 3758
  ident: bib0143
  article-title: Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation
  publication-title: Blood
– volume: 27
  start-page: 103
  year: 2021
  end-page: 104
  ident: bib0002
  article-title: American Society for Transplantation and Cellular Therapy Infectious Diseases Guidelines: preface to the series
  publication-title: Transplant Cell Ther
– volume: 70
  start-page: 1525
  year: 2020
  end-page: 1533
  ident: bib0010
  article-title: A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation
  publication-title: Clin Infect Dis
– volume: 40
  start-page: 63
  year: 2008
  end-page: 67
  ident: bib0144
  article-title: Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells
  publication-title: Blood Cells Mol Dis
– volume: 25
  start-page: 369
  year: 2019
  end-page: 381
  ident: bib0006
  article-title: A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation
  publication-title: Biol Blood Marrow Transplant
– volume: 59
  start-page: 473
  year: 2014
  end-page: 481
  ident: bib0024
  article-title: Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation
  publication-title: Clin Infect Dis
– volume: 19
  start-page: 233
  year: 1997
  end-page: 236
  ident: bib0040
  article-title: No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group
  publication-title: Bone Marrow Transplant
– volume: 17
  start-page: 889
  year: 2018
  end-page: 911
  ident: bib0137
  article-title: A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection
  publication-title: Expert Rev Vaccines
– volume: 200
  year: 2018
  ident: bib0021
  article-title: Racial and ethnic differences in the prevalence of congenital cytomegalovirus infection
  publication-title: J Pediatr
– volume: 216
  start-page: 926
  year: 2017
  end-page: 928
  ident: bib0149
  article-title: Adoptive immunotherapy of viral infections: should infectious disease embrace cellular immunotherapy?
  publication-title: J Infect Dis
– volume: 17
  start-page: 1602
  year: 2011
  end-page: 1611
  ident: bib0086
  article-title: Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies
  publication-title: Biol Blood Marrow Transplant
– volume: 21
  start-page: 1622
  year: 2021
  end-page: 1628
  ident: bib0063
  article-title: Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection
  publication-title: Am J Transplant
– volume: 132
  start-page: 1438
  year: 2018
  end-page: 1451
  ident: bib0083
  article-title: Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies
  publication-title: Blood
– volume: 150
  start-page: 209
  year: 2010
  end-page: 217
  ident: bib0031
  article-title: Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction
  publication-title: Br J Haematol
– volume: 91
  start-page: 877
  year: 2010
  end-page: 885
  ident: bib0164
  article-title: Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion
  publication-title: Int J Hematol
– volume: 83
  start-page: 2678
  year: 2017
  end-page: 2686
  ident: bib0048
  article-title: Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment
  publication-title: Br J Clin Pharmacol
– volume: 82
  start-page: 433
  year: 2010
  end-page: 440
  ident: bib0129
  article-title: Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital
  publication-title: J Med Virol
– volume: 3
  start-page: ofw107
  year: 2016
  ident: bib0132
  article-title: Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients
  publication-title: Open Forum Infect Dis
– reference: Corp MSD. PREVYMIS: Package Insert and Label Information. 2017.
– volume: 185
  start-page: 273
  year: 2002
  end-page: 282
  ident: bib0025
  article-title: High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection
  publication-title: J Infect Dis
– volume: 51
  start-page: 1134
  year: 2016
  end-page: 1136
  ident: bib0166
  article-title: The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide
  publication-title: Bone Marrow Transplant
– volume: 137
  start-page: 3291
  year: 2021
  end-page: 3305
  ident: bib0016
  article-title: Post-transplant cyclophosphamide (PTCy) is associated with increased cytomegalovirus infection: A CIBMTR Analysis
  publication-title: Blood
– volume: 100
  start-page: 2087
  year: 2021
  end-page: 2093
  ident: bib0057
  article-title: Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data
  publication-title: Ann Hematol
– volume: 25
  start-page: 757
  year: 2000
  end-page: 763
  ident: bib0101
  article-title: Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
  publication-title: Bone Marrow Transplant
– volume: 122
  start-page: 3359
  year: 2013
  end-page: 3364
  ident: bib0150
  article-title: CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT
  publication-title: Blood
– volume: 51
  start-page: 1113
  year: 2016
  end-page: 1120
  ident: bib0013
  article-title: Impact of early CMV reactivation in cord blood stem cell recipients in the current era
  publication-title: Bone Marrow Transplant
– volume: 18
  start-page: 1753
  year: 2012
  end-page: 1758
  ident: bib0111
  article-title: Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation
  publication-title: Biol Blood Marrow Transplant
– volume: 220
  start-page: 411
  year: 2019
  end-page: 419
  ident: bib0120
  article-title: Phase 1 clinical trial of a conditionally replication-defective human cytomegalovirus (CMV) vaccine in CMV-seronegative subjects
  publication-title: J Infect Dis
– volume: 111
  start-page: 782
  year: 2000
  end-page: 790
  ident: bib0102
  article-title: Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation
  publication-title: Br J Haematol
– volume: 27
  year: 2021
  ident: bib0059
  article-title: Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis
  publication-title: Transplant Cell Ther
– volume: 162
  start-page: 1
  year: 2015
  end-page: 10
  ident: bib0100
  article-title: Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial
  publication-title: Ann Intern Med
– volume: 22
  start-page: 2047
  year: 2016
  end-page: 2055
  ident: bib0165
  article-title: Comparative outcomes after haploidentical or unrelated donor bone marrow or blood stem cell transplantation in adult patients with hematological malignancies
  publication-title: Biol Blood Marrow Transplant
– volume: 314
  start-page: 1006
  year: 1986
  end-page: 1010
  ident: bib0041
  article-title: Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation
  publication-title: N Engl J Med
– volume: 118
  start-page: 173
  year: 1993
  end-page: 178
  ident: bib0068
  article-title: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
  publication-title: Ann Intern Med
– volume: 33
  start-page: e13512
  year: 2019
  ident: bib0126
  article-title: Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice
  publication-title: Clin Transplant
– volume: 14
  start-page: 644
  year: 2012
  end-page: 655
  ident: bib0004
  article-title: Human cytomegalovirus persistence
  publication-title: Cell Microbiol
– volume: 22
  year: 2016
  ident: bib0099
  article-title: Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status
  publication-title: Clin Microbiol Infect
– volume: 24
  start-page: 1049
  year: 2018
  end-page: 1056
  ident: bib0038
  article-title: Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most
  publication-title: Biol Blood Marrow Transplant
– volume: 94
  start-page: 1677
  year: 2015
  end-page: 1688
  ident: bib0171
  article-title: Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings
  publication-title: Ann Hematol
– volume: 55
  start-page: 1678
  year: 2012
  end-page: 1689
  ident: bib0125
  article-title: State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician
  publication-title: Clin Infect Dis
– volume: 118
  start-page: 179
  year: 1993
  end-page: 184
  ident: bib0069
  article-title: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo- controlled, double-blind trial
  publication-title: Ann Intern Med
– volume: 33
  start-page: 197
  year: 2004
  end-page: 204
  ident: bib0162
  article-title: Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens
  publication-title: Bone Marrow Transplant
– volume: 2
  start-page: 2159
  year: 2018
  end-page: 2175
  ident: bib0080
  article-title: Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation
  publication-title: Blood Adv
– volume: 26
  start-page: 1963
  year: 2020
  end-page: 1970
  ident: bib0058
  article-title: Letermovir prophylaxis decreases burden of cytomegalovirus (CMV) in patients at high risk for CMV disease following hematopoietic cell transplant
  publication-title: Biol Blood Marrow Transplant
– volume: 13
  start-page: 898
  year: 2009
  end-page: 905
  ident: bib0154
  article-title: Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors
  publication-title: Pediatr Transplant
– volume: 26
  start-page: 23
  year: 2000
  end-page: 29
  ident: bib0073
  article-title: Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study
  publication-title: Bone Marrow Transplant
– volume: 28
  start-page: 879
  year: 2001
  end-page: 881
  ident: bib0093
  article-title: Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections
  publication-title: Bone Marrow Transplant
– volume: 17
  start-page: 510
  year: 2015
  end-page: 517
  ident: bib0156
  article-title: Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation
  publication-title: Transpl Infect Dis
– volume: 19
  start-page: e12629
  year: 2017
  ident: bib0170
  article-title: Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
  publication-title: Transpl Infect Dis
– volume: 41
  start-page: 1310
  year: 2001
  end-page: 1319
  ident: bib0030
  article-title: Evidence-based recommendations for the use of WBC-reduced cellular blood components
  publication-title: Transfusion
– volume: 219
  start-page: 898
  year: 2019
  end-page: 907
  ident: bib0128
  article-title: The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients
  publication-title: J Infect Dis
– volume: 64
  start-page: 108
  year: 1997
  end-page: 113
  ident: bib0042
  article-title: Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture
  publication-title: Transplantation
– volume: 138
  start-page: 34
  year: 2021
  end-page: 43
  ident: bib0065
  article-title: Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation
  publication-title: Blood
– volume: 37
  start-page: 7437
  year: 2019
  end-page: 7442
  ident: bib0135
  article-title: Vaccination against the human cytomegalovirus
  publication-title: Vaccine
– volume: 24
  start-page: 2088
  year: 2018
  end-page: 2093
  ident: bib0157
  article-title: Deleterious effect of steroids on cytomegalovirus infection rate after allogeneic stem cell transplantation depends on pretransplant cytomegalovirus serostatus of donors and recipients
  publication-title: Biol Blood Marrow Transplant
– volume: 98
  start-page: 1626
  year: 2001
  ident: bib0094
  article-title: Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients
  publication-title: Blood
– volume: 99
  start-page: 1159
  year: 2002
  end-page: 1164
  ident: bib0047
  article-title: Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation
  publication-title: Blood
– volume: 17
  start-page: 664
  year: 2011
  end-page: 673
  ident: bib0071
  article-title: An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients
  publication-title: Biol Blood Marrow Transplant
– volume: 45
  start-page: 1126
  year: 2007
  end-page: 1132
  ident: bib0176
  article-title: Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer
  publication-title: J Clin Microbiol
– volume: 107
  start-page: 3002
  year: 2006
  end-page: 3008
  ident: bib0091
  article-title: Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation
  publication-title: Blood
– volume: 21
  year: 2019
  ident: bib0060
  article-title: Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience
  publication-title: Transpl Infect Dis
– volume: 9
  start-page: 486
  year: 2020
  end-page: 489
  ident: bib0118
  article-title: Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient
  publication-title: J Pediatric Infect Dis Soc
– volume: 112
  start-page: 3974
  year: 2008
  end-page: 3981
  ident: bib0146
  article-title: Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation
  publication-title: Blood
– volume: 101
  year: 2016
  ident: bib0167
  article-title: Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide
  publication-title: Haematologica
– volume: 99
  start-page: 3050
  year: 2002
  ident: 10.1016/j.jtct.2021.05.001_bib0079
  article-title: Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants
  publication-title: Blood
  doi: 10.1182/blood.V99.8.3050
– volume: 150
  start-page: 209
  year: 2010
  ident: 10.1016/j.jtct.2021.05.001_bib0031
  article-title: Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2010.08227.x
– volume: 40
  start-page: 63
  year: 2008
  ident: 10.1016/j.jtct.2021.05.001_bib0144
  article-title: Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells
  publication-title: Blood Cells Mol Dis
  doi: 10.1016/j.bcmd.2007.07.003
– volume: 18
  start-page: 1687
  year: 2012
  ident: 10.1016/j.jtct.2021.05.001_bib0007
  article-title: Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2012.05.015
– volume: 5
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0076
  article-title: A survey of pediatric bone marrow transplant centers regarding local cytomegalovirus prophylaxis management practices and interest in a future randomized trial
  publication-title: ID Week Vol
– volume: 185
  start-page: 273
  year: 2002
  ident: 10.1016/j.jtct.2021.05.001_bib0025
  article-title: High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection
  publication-title: J Infect Dis
  doi: 10.1086/338624
– volume: 90
  start-page: 2502
  year: 1997
  ident: 10.1016/j.jtct.2021.05.001_bib0092
  article-title: Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome
  publication-title: Blood
  doi: 10.1182/blood.V90.6.2502
– volume: 24
  start-page: 353
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0105
  article-title: Prevention of cytomegalovirus reactivation in haploidentical stem cell transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2017.09.018
– volume: 220
  start-page: 411
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0120
  article-title: Phase 1 clinical trial of a conditionally replication-defective human cytomegalovirus (CMV) vaccine in CMV-seronegative subjects
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiz141
– volume: 98
  start-page: 760
  year: 1997
  ident: 10.1016/j.jtct.2021.05.001_bib0160
  article-title: Transplantation of HLA-mismatched CD34+ selected cells in patients with advanced malignancies: severe immunodeficiency and related complications
  publication-title: Br J Haematol
  doi: 10.1046/j.1365-2141.1997.2773094.x
– volume: 18
  start-page: 1753
  year: 2012
  ident: 10.1016/j.jtct.2021.05.001_bib0111
  article-title: Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2012.06.008
– volume: 99
  start-page: 3916
  year: 2002
  ident: 10.1016/j.jtct.2021.05.001_bib0140
  article-title: Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy
  publication-title: Blood
  doi: 10.1182/blood.V99.11.3916
– volume: 219
  start-page: 898
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0128
  article-title: The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiy592
– volume: 21
  start-page: e13096
  issue: 4
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0172
  article-title: Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia
  publication-title: Transpl Infect Dis
  doi: 10.1111/tid.13096
– volume: 13
  start-page: 707
  year: 2007
  ident: 10.1016/j.jtct.2021.05.001_bib0145
  article-title: Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2007.02.004
– volume: 24
  start-page: 2088
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0157
  article-title: Deleterious effect of steroids on cytomegalovirus infection rate after allogeneic stem cell transplantation depends on pretransplant cytomegalovirus serostatus of donors and recipients
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2018.05.001
– volume: 97
  start-page: 8039
  year: 2000
  ident: 10.1016/j.jtct.2021.05.001_bib0087
  article-title: Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.140123497
– volume: 33
  year: 2021
  ident: 10.1016/j.jtct.2021.05.001_bib0133
  article-title: A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.100787
– volume: 218
  start-page: S7
  issue: suppl_1
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0001
  article-title: The damage-response framework as a tool for the physician-scientist to understand the pathogenesis of infectious diseases
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiy083
– volume: 343
  start-page: 749
  issue: 8900
  year: 1994
  ident: 10.1016/j.jtct.2021.05.001_bib0078
  article-title: Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group
  publication-title: Lancet
  doi: 10.1016/S0140-6736(94)91835-X
– volume: 86
  start-page: 2815
  year: 1995
  ident: 10.1016/j.jtct.2021.05.001_bib0096
  article-title: Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
  publication-title: Blood
  doi: 10.1182/blood.V86.7.2815.2815
– volume: 116
  start-page: 4360
  year: 2010
  ident: 10.1016/j.jtct.2021.05.001_bib0141
  article-title: Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation
  publication-title: Blood
  doi: 10.1182/blood-2010-01-262089
– volume: 40
  start-page: 865
  year: 2007
  ident: 10.1016/j.jtct.2021.05.001_bib0131
  article-title: Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1705825
– volume: 7
  start-page: 9
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0050
  article-title: Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects
  publication-title: Clin Pharmacol Drug Dev
  doi: 10.1002/cpdd.388
– volume: 318
  start-page: 70
  year: 1988
  ident: 10.1016/j.jtct.2021.05.001_bib0077
  article-title: Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198801143180202
– volume: 13
  start-page: 783
  year: 1994
  ident: 10.1016/j.jtct.2021.05.001_bib0072
  article-title: CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections
  publication-title: Bone Marrow Transplant
– volume: 6
  start-page: 280
  year: 2000
  ident: 10.1016/j.jtct.2021.05.001_bib0152
  article-title: CMV antigenemia following bone marrow transplantation: risk factors and outcomes
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/S1083-8791(00)70010-3
– volume: 24
  start-page: 1049
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0038
  article-title: Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2018.02.006
– volume: 8
  start-page: e74744
  issue: 10
  year: 2013
  ident: 10.1016/j.jtct.2021.05.001_bib0130
  article-title: Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0074744
– volume: 68
  start-page: 1420
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0097
  article-title: Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciy696
– volume: 216
  start-page: 926
  year: 2017
  ident: 10.1016/j.jtct.2021.05.001_bib0149
  article-title: Adoptive immunotherapy of viral infections: should infectious disease embrace cellular immunotherapy?
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jix360
– volume: 216
  start-page: 945
  year: 2017
  ident: 10.1016/j.jtct.2021.05.001_bib0142
  article-title: Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jix357
– volume: 127
  start-page: 2427
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0009
  article-title: Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
  publication-title: Blood
  doi: 10.1182/blood-2015-11-679639
– volume: 127
  start-page: 260
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0037
  article-title: The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy
  publication-title: Blood
  doi: 10.1182/blood-2015-08-663823
– volume: 94
  start-page: 4029
  year: 1999
  ident: 10.1016/j.jtct.2021.05.001_bib0114
  article-title: Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation
  publication-title: Blood
  doi: 10.1182/blood.V94.12.4029
– volume: 74
  start-page: 2820
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0119
  article-title: Letermovir in paediatric HSCT recipients
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkz218
– volume: 14
  start-page: 1185
  year: 2021
  ident: 10.1016/j.jtct.2021.05.001_bib0117
  article-title: Off-label use of letermovir as preemptive anti-cytomegalovirus therapy in a pediatric allogeneic peripheral blood stem cell transplant
  publication-title: Infect Drug Resist
  doi: 10.2147/IDR.S296927
– volume: 23
  start-page: 3447
  year: 2005
  ident: 10.1016/j.jtct.2021.05.001_bib0159
  article-title: Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.09.117
– volume: 37
  start-page: 307
  year: 2006
  ident: 10.1016/j.jtct.2021.05.001_bib0107
  article-title: Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1705249
– volume: 49
  start-page: 1683
  year: 2003
  ident: 10.1016/j.jtct.2021.05.001_bib0045
  article-title: Quantitative real-time PCR compared with pp65 antigen detection for cytomegalovirus (CMV) in 1122 blood specimens from 77 patients after allogeneic stem cell transplantation: which test better predicts CMV disease development?
  publication-title: Clin Chem
  doi: 10.1373/49.10.1683
– volume: 65
  issue: 6
  year: 2021
  ident: 10.1016/j.jtct.2021.05.001_bib0054
  article-title: Concomitant administration of posaconazole and isavuconazole with letermovir: clinical and pharmacological considerations
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00274-21
– volume: 26
  start-page: 978
  year: 2020
  ident: 10.1016/j.jtct.2021.05.001_bib0064
  article-title: Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French Compassionate Program
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2020.01.027
– volume: 17
  start-page: 510
  year: 2015
  ident: 10.1016/j.jtct.2021.05.001_bib0156
  article-title: Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation
  publication-title: Transpl Infect Dis
  doi: 10.1111/tid.12398
– volume: 56
  start-page: 1171
  year: 2021
  ident: 10.1016/j.jtct.2021.05.001_bib0116
  article-title: Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study
  publication-title: Bone Marrow Transplant
  doi: 10.1038/s41409-020-01166-w
– volume: 8
  issue: 362
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0136
  article-title: A replication-defective human cytomegalovirus vaccine for prevention of congenital infection
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aaf9387
– volume: 137
  start-page: 3291
  issue: 23
  year: 2021
  ident: 10.1016/j.jtct.2021.05.001_bib0016
  article-title: Post-transplant cyclophosphamide (PTCy) is associated with increased cytomegalovirus infection: A CIBMTR Analysis
  publication-title: Blood
  doi: 10.1182/blood.2020009362
– volume: 22
  start-page: 2047
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0165
  article-title: Comparative outcomes after haploidentical or unrelated donor bone marrow or blood stem cell transplantation in adult patients with hematological malignancies
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2016.08.003
– volume: 29
  start-page: e2017
  issue: 1
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0019
  article-title: Going beyond serology for stratifying the risk of CMV infection in transplant recipients
  publication-title: Rev Med Virol
  doi: 10.1002/rmv.2017
– volume: 21
  start-page: 1622
  year: 2021
  ident: 10.1016/j.jtct.2021.05.001_bib0063
  article-title: Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection
  publication-title: Am J Transplant
  doi: 10.1111/ajt.16450
– volume: 24
  start-page: 69
  year: 1999
  ident: 10.1016/j.jtct.2021.05.001_bib0108
  article-title: Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1701827
– volume: 18
  start-page: 1391
  year: 2012
  ident: 10.1016/j.jtct.2021.05.001_bib0023
  article-title: Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2012.02.008
– volume: 26
  start-page: 1963
  year: 2020
  ident: 10.1016/j.jtct.2021.05.001_bib0058
  article-title: Letermovir prophylaxis decreases burden of cytomegalovirus (CMV) in patients at high risk for CMV disease following hematopoietic cell transplant
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2020.07.002
– volume: 97
  start-page: 388
  year: 2001
  ident: 10.1016/j.jtct.2021.05.001_bib0095
  article-title: Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
  publication-title: Blood
  doi: 10.1182/blood.V97.2.388
– volume: 26
  start-page: 23
  year: 2000
  ident: 10.1016/j.jtct.2021.05.001_bib0073
  article-title: Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1702450
– volume: 56
  start-page: 853
  year: 2021
  ident: 10.1016/j.jtct.2021.05.001_bib0061
  article-title: Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data
  publication-title: Bone Marrow Transplant
  doi: 10.1038/s41409-020-01082-z
– volume: 28
  start-page: 879
  year: 2001
  ident: 10.1016/j.jtct.2021.05.001_bib0093
  article-title: Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1703251
– volume: 64
  start-page: 87
  year: 2017
  ident: 10.1016/j.jtct.2021.05.001_bib0003
  article-title: Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciw668
– volume: 7
  start-page: 122
  issue: 3-4
  year: 2005
  ident: 10.1016/j.jtct.2021.05.001_bib0113
  article-title: Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program
  publication-title: Transpl Infect Dis
  doi: 10.1111/j.1399-3062.2005.000111.x
– volume: 93
  issue: 23
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0134
  article-title: A replication-defective human cytomegalovirus vaccine elicits humoral immune responses analogous to those with natural infection
  publication-title: J Virol
  doi: 10.1128/JVI.00747-19
– volume: 314
  start-page: 1006
  year: 1986
  ident: 10.1016/j.jtct.2021.05.001_bib0041
  article-title: Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198604173141602
– volume: 200
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0021
  article-title: Racial and ethnic differences in the prevalence of congenital cytomegalovirus infection
  publication-title: J Pediatr
  doi: 10.1016/j.jpeds.2018.04.043
– volume: 51
  start-page: 718
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0085
  article-title: Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2015.303
– volume: 91
  start-page: 78
  year: 2006
  ident: 10.1016/j.jtct.2021.05.001_bib0034
  article-title: Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation
  publication-title: Haematologica
– volume: 40
  start-page: 125
  year: 2007
  ident: 10.1016/j.jtct.2021.05.001_bib0035
  article-title: Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1705699
– volume: 75
  start-page: 775
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0052
  article-title: Clinically significant drug interaction: letermovir and voriconazole
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkz499
– volume: 55
  start-page: 87
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0084
  article-title: Curative therapies: allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease
  publication-title: Semin Hematol
  doi: 10.1053/j.seminhematol.2018.04.011
– volume: 83
  start-page: 2678
  year: 2017
  ident: 10.1016/j.jtct.2021.05.001_bib0048
  article-title: Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.13376
– volume: 59
  start-page: 473
  year: 2014
  ident: 10.1016/j.jtct.2021.05.001_bib0024
  article-title: Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciu364
– volume: 99
  start-page: 1159
  year: 2002
  ident: 10.1016/j.jtct.2021.05.001_bib0047
  article-title: Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation
  publication-title: Blood
  doi: 10.1182/blood.V99.4.1159
– volume: 72
  start-page: 265
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0112
  article-title: Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant
  publication-title: J Infect
  doi: 10.1016/j.jinf.2015.11.005
– volume: 17
  start-page: 747
  year: 2017
  ident: 10.1016/j.jtct.2021.05.001_bib0098
  article-title: Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients
  publication-title: BMC Infect Dis
  doi: 10.1186/s12879-017-2854-2
– volume: 107
  start-page: 3002
  year: 2006
  ident: 10.1016/j.jtct.2021.05.001_bib0091
  article-title: Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation
  publication-title: Blood
  doi: 10.1182/blood-2005-09-3786
– volume: 27
  start-page: 103
  year: 2021
  ident: 10.1016/j.jtct.2021.05.001_bib0002
  article-title: American Society for Transplantation and Cellular Therapy Infectious Diseases Guidelines: preface to the series
  publication-title: Transplant Cell Ther
  doi: 10.1016/j.jtct.2020.10.004
– volume: 122
  start-page: 3359
  year: 2013
  ident: 10.1016/j.jtct.2021.05.001_bib0150
  article-title: CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT
  publication-title: Blood
  doi: 10.1182/blood-2013-05-499830
– volume: 49
  start-page: 276
  year: 2014
  ident: 10.1016/j.jtct.2021.05.001_bib0075
  article-title: Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2013.164
– volume: 172
  start-page: 306
  year: 2020
  ident: 10.1016/j.jtct.2021.05.001_bib0138
  article-title: Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial
  publication-title: Ann Intern Med
  doi: 10.7326/M19-2511
– volume: 113
  start-page: 6465
  year: 2009
  ident: 10.1016/j.jtct.2021.05.001_bib0033
  article-title: Impact of donor CMV-status on viral infection and reconstitution of multi-function CMV-specific T-cells in CMV-positive transplant recipients
  publication-title: Blood
  doi: 10.1182/blood-2009-02-203307
– volume: 51
  start-page: 1134
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0166
  article-title: The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2016.69
– volume: 41
  start-page: 1310
  year: 2001
  ident: 10.1016/j.jtct.2021.05.001_bib0030
  article-title: Evidence-based recommendations for the use of WBC-reduced cellular blood components
  publication-title: Transfusion
  doi: 10.1046/j.1537-2995.2001.41101310.x
– volume: 13
  start-page: 898
  year: 2009
  ident: 10.1016/j.jtct.2021.05.001_bib0154
  article-title: Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: a retrospective study of the risk factors
  publication-title: Pediatr Transplant
  doi: 10.1111/j.1399-3046.2008.01084.x
– volume: 377
  start-page: 2433
  year: 2017
  ident: 10.1016/j.jtct.2021.05.001_bib0005
  article-title: Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1706640
– volume: 164
  start-page: 483
  year: 1991
  ident: 10.1016/j.jtct.2021.05.001_bib0039
  article-title: Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant
  publication-title: J Infect Dis
  doi: 10.1093/infdis/164.3.483
– volume: 11
  start-page: 136
  year: 2005
  ident: 10.1016/j.jtct.2021.05.001_bib0104
  article-title: Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2004.11.016
– volume: 55
  start-page: 780
  year: 2020
  ident: 10.1016/j.jtct.2021.05.001_bib0062
  article-title: Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation
  publication-title: Bone Marrow Transplant
  doi: 10.1038/s41409-019-0730-y
– volume: 19
  start-page: 233
  year: 1997
  ident: 10.1016/j.jtct.2021.05.001_bib0040
  article-title: No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1700649
– volume: 166
  start-page: 473
  year: 1992
  ident: 10.1016/j.jtct.2021.05.001_bib0074
  article-title: Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients
  publication-title: J Infect Dis
  doi: 10.1093/infdis/166.3.473
– volume: 112
  start-page: 3974
  year: 2008
  ident: 10.1016/j.jtct.2021.05.001_bib0146
  article-title: Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation
  publication-title: Blood
  doi: 10.1182/blood-2008-06-161695
– volume: 14
  start-page: 141
  year: 2012
  ident: 10.1016/j.jtct.2021.05.001_bib0153
  article-title: A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group
  publication-title: Transpl Infect Dis
  doi: 10.1111/j.1399-3062.2011.00706.x
– volume: 91
  start-page: 877
  year: 2010
  ident: 10.1016/j.jtct.2021.05.001_bib0164
  article-title: Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion
  publication-title: Int J Hematol
  doi: 10.1007/s12185-010-0597-6
– volume: 46
  start-page: 3311
  year: 2008
  ident: 10.1016/j.jtct.2021.05.001_bib0043
  article-title: Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00797-08
– volume: 33
  start-page: 197
  year: 2004
  ident: 10.1016/j.jtct.2021.05.001_bib0162
  article-title: Influence of cytomegalovirus (CMV) sero-positivity on CMV infection, lymphocyte recovery and non-CMV infections following T-cell-depleted allogeneic stem cell transplantation: a comparison between two T-cell depletion regimens
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1704334
– volume: 2
  start-page: 2159
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0080
  article-title: Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2018016493
– volume: 82
  start-page: 433
  year: 2010
  ident: 10.1016/j.jtct.2021.05.001_bib0129
  article-title: Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital
  publication-title: J Med Virol
  doi: 10.1002/jmv.21727
– volume: 175
  start-page: 1490
  year: 1997
  ident: 10.1016/j.jtct.2021.05.001_bib0110
  article-title: Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation
  publication-title: J Infect Dis
  doi: 10.1086/516484
– volume: 33
  start-page: e13512
  issue: 9
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0126
  article-title: Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice
  publication-title: Clin Transplant
  doi: 10.1111/ctr.13512
– volume: 45
  start-page: 1126
  year: 2007
  ident: 10.1016/j.jtct.2021.05.001_bib0176
  article-title: Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.01670-06
– volume: 18
  start-page: 92
  year: 2012
  ident: 10.1016/j.jtct.2021.05.001_bib0036
  article-title: CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2011.05.015
– volume: 21
  start-page: 355
  year: 1998
  ident: 10.1016/j.jtct.2021.05.001_bib0163
  article-title: Allogeneic peripheral stem cell transplantation using positively selected CD34+ cells from HLA-mismatched donors
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1701095
– volume: 34
  start-page: e13866
  issue: 7
  year: 2020
  ident: 10.1016/j.jtct.2021.05.001_bib0056
  article-title: Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients
  publication-title: Clin Transplant
  doi: 10.1111/ctr.13866
– volume: 378
  start-page: 35
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0115
  article-title: Myeloablative autologous stem-cell transplantation for severe scleroderma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1703327
– volume: 101
  start-page: 2426
  year: 2003
  ident: 10.1016/j.jtct.2021.05.001_bib0032
  article-title: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial
  publication-title: Blood
  doi: 10.1182/blood-2002-03-0932
– volume: 98
  start-page: 1626
  year: 2001
  ident: 10.1016/j.jtct.2021.05.001_bib0094
  article-title: Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients
  publication-title: Blood
  doi: 10.1182/blood.V98.5.1626
– volume: 21
  start-page: e13049
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0158
  article-title: Impact of cumulative steroid dose on infectious diseases after allogenic hematopoietic stem cell transplantation
  publication-title: Transpl Infect Dis
  doi: 10.1111/tid.13049
– volume: 15
  start-page: 694
  year: 2009
  ident: 10.1016/j.jtct.2021.05.001_bib0022
  article-title: Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2009.02.009
– volume: 58
  start-page: 897
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0053
  article-title: Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects
  publication-title: J Clin Pharmacol
  doi: 10.1002/jcph.1094
– volume: 37
  start-page: 851
  year: 2006
  ident: 10.1016/j.jtct.2021.05.001_bib0088
  article-title: Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1705341
– volume: 34
  start-page: 347
  year: 2002
  ident: 10.1016/j.jtct.2021.05.001_bib0028
  article-title: Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors
  publication-title: Scand J Infect Dis
  doi: 10.1080/00365540110080412
– volume: 17
  start-page: 889
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0137
  article-title: A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection
  publication-title: Expert Rev Vaccines
  doi: 10.1080/14760584.2018.1526085
– volume: 31
  start-page: 813
  year: 2003
  ident: 10.1016/j.jtct.2021.05.001_bib0106
  article-title: Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1703916
– volume: 55
  start-page: 1678
  year: 2012
  ident: 10.1016/j.jtct.2021.05.001_bib0125
  article-title: State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cis818
– volume: 15
  start-page: 1
  year: 2001
  ident: 10.1016/j.jtct.2021.05.001_bib0026
  article-title: Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction
  publication-title: Transfus Med Rev
  doi: 10.1053/tmrv.2001.19946
– volume: 132
  start-page: 1438
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0083
  article-title: Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies
  publication-title: Blood
  doi: 10.1182/blood-2018-01-828277
– volume: 71
  start-page: 2365
  year: 2020
  ident: 10.1016/j.jtct.2021.05.001_bib0127
  article-title: Cytomegalovirus (CMV) cell-mediated immunity and cmv infection after allogeneic hematopoietic cell transplantation: the REACT Study
  publication-title: Clin Infect Dis
– volume: 174
  start-page: 907
  year: 1996
  ident: 10.1016/j.jtct.2021.05.001_bib0109
  article-title: Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation
  publication-title: J Infect Dis
  doi: 10.1093/infdis/174.5.907
– volume: 82
  year: 1993
  ident: 10.1016/j.jtct.2021.05.001_bib0175
  article-title: Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation
  publication-title: Blood
  doi: 10.1182/blood.V82.5.1672.bloodjournal8251672
– volume: 9
  start-page: 102
  year: 2007
  ident: 10.1016/j.jtct.2021.05.001_bib0089
  article-title: Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation
  publication-title: Transpl Infect Dis
  doi: 10.1111/j.1399-3062.2006.00183.x
– ident: 10.1016/j.jtct.2021.05.001_bib0055
– volume: 9
  start-page: 486
  year: 2020
  ident: 10.1016/j.jtct.2021.05.001_bib0118
  article-title: Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient
  publication-title: J Pediatric Infect Dis Soc
  doi: 10.1093/jpids/piz050
– volume: 3
  start-page: e87
  issue: 2
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0139
  article-title: Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial
  publication-title: Lancet Haematol
  doi: 10.1016/S2352-3026(15)00246-X
– volume: 26
  start-page: 1363
  year: 2020
  ident: 10.1016/j.jtct.2021.05.001_bib0015
  article-title: Favorable effect of cytomegalovirus reactivation on outcomes in cord blood transplant and its differences among disease risk or type
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2020.04.002
– volume: 18
  start-page: 1835
  year: 2012
  ident: 10.1016/j.jtct.2021.05.001_bib0177
  article-title: Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2012.07.003
– volume: 12
  start-page: 322
  year: 2010
  ident: 10.1016/j.jtct.2021.05.001_bib0018
  article-title: Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy
  publication-title: Transpl Infect Dis
  doi: 10.1111/j.1399-3062.2010.00504.x
– volume: 25
  start-page: 757
  year: 2000
  ident: 10.1016/j.jtct.2021.05.001_bib0101
  article-title: Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1702226
– volume: 121
  start-page: 3745
  year: 2013
  ident: 10.1016/j.jtct.2021.05.001_bib0143
  article-title: Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation
  publication-title: Blood
  doi: 10.1182/blood-2012-08-448977
– volume: 118
  start-page: 5689
  year: 2011
  ident: 10.1016/j.jtct.2021.05.001_bib0081
  article-title: Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients
  publication-title: Blood
  doi: 10.1182/blood-2011-06-361618
– volume: 17
  start-page: 664
  year: 2011
  ident: 10.1016/j.jtct.2021.05.001_bib0071
  article-title: An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2010.07.026
– volume: 381
  start-page: 1136
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0121
  article-title: Maribavir for preemptive treatment of cytomegalovirus reactivation
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1714656
– volume: 59
  start-page: 6588
  year: 2015
  ident: 10.1016/j.jtct.2021.05.001_bib0122
  article-title: Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01623-15
– volume: 3
  start-page: ofw107
  issue: 2
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0132
  article-title: Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients
  publication-title: Open Forum Infect Dis
  doi: 10.1093/ofid/ofw107
– volume: 94
  start-page: 1677
  year: 2015
  ident: 10.1016/j.jtct.2021.05.001_bib0171
  article-title: Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings
  publication-title: Ann Hematol
  doi: 10.1007/s00277-015-2423-y
– volume: 86
  start-page: 3598
  year: 1995
  ident: 10.1016/j.jtct.2021.05.001_bib0027
  article-title: Comparison of filtered blood (FB) to seronegative blood products (SB) for prevention of cytomegalovirus (CMV) infection after marrow transplant
  publication-title: Blood
  doi: 10.1182/blood.V86.9.3598.bloodjournal8693598
– volume: 37
  start-page: 7437
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0135
  article-title: Vaccination against the human cytomegalovirus
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2018.02.089
– volume: 221
  start-page: 1117
  year: 2020
  ident: 10.1016/j.jtct.2021.05.001_bib0124
  article-title: Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiz577
– volume: 162
  start-page: 1
  year: 2015
  ident: 10.1016/j.jtct.2021.05.001_bib0100
  article-title: Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial
  publication-title: Ann Intern Med
  doi: 10.7326/M13-2729
– volume: 23
  start-page: e13548
  issue: 3
  year: 2021
  ident: 10.1016/j.jtct.2021.05.001_bib0017
  article-title: Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance
  publication-title: Transpl Infect Dis
  doi: 10.1111/tid.13548
– volume: 22
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0099
  article-title: Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status
  publication-title: Clin Microbiol Infect
  doi: 10.1016/j.cmi.2015.11.006
– volume: 122
  start-page: 1316
  year: 2013
  ident: 10.1016/j.jtct.2021.05.001_bib0012
  article-title: CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia
  publication-title: Blood
  doi: 10.1182/blood-2013-02-487074
– volume: 121
  start-page: 5113
  year: 2013
  ident: 10.1016/j.jtct.2021.05.001_bib0148
  article-title: Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
  publication-title: Blood
  doi: 10.1182/blood-2013-02-486324
– volume: 137
  start-page: 58
  year: 2009
  ident: 10.1016/j.jtct.2021.05.001_bib0020
  article-title: Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III
  publication-title: Epidemiol Infect
  doi: 10.1017/S0950268808000551
– volume: 25
  start-page: 369
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0006
  article-title: A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2018.09.038
– volume: 99
  start-page: 4357
  year: 2002
  ident: 10.1016/j.jtct.2021.05.001_bib0161
  article-title: High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
  publication-title: Blood
  doi: 10.1182/blood.V99.12.4357
– volume: 100
  start-page: 2087
  issue: 8
  year: 2021
  ident: 10.1016/j.jtct.2021.05.001_bib0057
  article-title: Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data
  publication-title: Ann Hematol
  doi: 10.1007/s00277-020-04362-2
– volume: 20
  start-page: 1573
  year: 2014
  ident: 10.1016/j.jtct.2021.05.001_bib0168
  article-title: Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2014.05.029
– volume: 3
  start-page: e119
  issue: 3
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0008
  article-title: Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study
  publication-title: Lancet Haematol
  doi: 10.1016/S2352-3026(15)00289-6
– volume: 20
  start-page: 1703
  year: 2020
  ident: 10.1016/j.jtct.2021.05.001_bib0123
  article-title: Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation
  publication-title: Am J Transplant
  doi: 10.1111/ajt.15764
– volume: 66
  start-page: 1330
  year: 1998
  ident: 10.1016/j.jtct.2021.05.001_bib0151
  article-title: Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
  publication-title: Transplantation
  doi: 10.1097/00007890-199811270-00012
– volume: 29
  start-page: 599
  year: 2002
  ident: 10.1016/j.jtct.2021.05.001_bib0046
  article-title: Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1703513
– volume: 101
  start-page: 407
  year: 2003
  ident: 10.1016/j.jtct.2021.05.001_bib0103
  article-title: Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity
  publication-title: Blood
  doi: 10.1182/blood-2002-03-0993
– volume: 118
  start-page: 173
  year: 1993
  ident: 10.1016/j.jtct.2021.05.001_bib0068
  article-title: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-118-3-199302010-00003
– volume: 93
  start-page: 1781
  year: 1999
  ident: 10.1016/j.jtct.2021.05.001_bib0070
  article-title: Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
  publication-title: Blood
  doi: 10.1182/blood.V93.5.1781
– volume: 21
  start-page: 2008
  year: 2015
  ident: 10.1016/j.jtct.2021.05.001_bib0014
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2015.07.019
– volume: 83
  start-page: 1944
  year: 2017
  ident: 10.1016/j.jtct.2021.05.001_bib0049
  article-title: Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.13292
– volume: 51
  start-page: 1602
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0169
  article-title: Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2016.216
– volume: 24
  start-page: 2094
  year: 2018
  ident: 10.1016/j.jtct.2021.05.001_bib0082
  article-title: A modified intensive strategy to prevent cytomegalovirus disease in seropositive umbilical cord blood transplantation recipients
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2018.05.008
– volume: 17
  start-page: 1602
  year: 2011
  ident: 10.1016/j.jtct.2021.05.001_bib0086
  article-title: Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2011.08.014
– volume: 36
  start-page: 749
  year: 2003
  ident: 10.1016/j.jtct.2021.05.001_bib0067
  article-title: Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation
  publication-title: Clin Infect Dis
  doi: 10.1086/367836
– volume: 70
  start-page: 1525
  year: 2020
  ident: 10.1016/j.jtct.2021.05.001_bib0010
  article-title: A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciz490
– volume: 88
  start-page: 4063
  year: 1996
  ident: 10.1016/j.jtct.2021.05.001_bib0178
  article-title: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study
  publication-title: Blood
  doi: 10.1182/blood.V88.10.4063.bloodjournal88104063
– volume: 21
  issue: 6
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0060
  article-title: Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience
  publication-title: Transpl Infect Dis
  doi: 10.1111/tid.13187
– volume: 103
  start-page: 832
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0174
  article-title: Clinical correlation of cytomegalovirus infection with CMV-specific CD8+ T-cell immune competence score and lymphocyte subsets in solid organ transplant recipients
  publication-title: Transplantation
  doi: 10.1097/TP.0000000000002396
– volume: 13
  start-page: 1106
  year: 2007
  ident: 10.1016/j.jtct.2021.05.001_bib0173
  article-title: Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2007.06.006
– volume: 59
  start-page: 1331
  year: 2019
  ident: 10.1016/j.jtct.2021.05.001_bib0051
  article-title: Pharmacokinetic drug-drug interactions between letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil
  publication-title: J Clin Pharmacol
  doi: 10.1002/jcph.1423
– volume: 19
  start-page: e12629
  issue: 1
  year: 2017
  ident: 10.1016/j.jtct.2021.05.001_bib0170
  article-title: Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
  publication-title: Transpl Infect Dis
  doi: 10.1111/tid.12629
– volume: 101
  start-page: 4195
  year: 2003
  ident: 10.1016/j.jtct.2021.05.001_bib0029
  article-title: Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products
  publication-title: Blood
  doi: 10.1182/blood-2002-10-3143
– volume: 27
  issue: 1
  year: 2021
  ident: 10.1016/j.jtct.2021.05.001_bib0059
  article-title: Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis
  publication-title: Transplant Cell Ther
  doi: 10.1016/j.bbmt.2020.10.009
– volume: 138
  start-page: 34
  issue: 1
  year: 2021
  ident: 10.1016/j.jtct.2021.05.001_bib0065
  article-title: Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation
  publication-title: Blood
  doi: 10.1182/blood.2020009396
– volume: 37
  start-page: 693
  year: 2006
  ident: 10.1016/j.jtct.2021.05.001_bib0090
  article-title: Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1705311
– volume: 9
  start-page: 16
  year: 2007
  ident: 10.1016/j.jtct.2021.05.001_bib0044
  article-title: Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation
  publication-title: Transpl Infect Dis
  doi: 10.1111/j.1399-3062.2006.00171.x
– volume: 111
  start-page: 782
  year: 2000
  ident: 10.1016/j.jtct.2021.05.001_bib0102
  article-title: Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation
  publication-title: Br J Haematol
– volume: 14
  start-page: 882
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0066
  article-title: Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology
  publication-title: J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2016.0093
– volume: 14
  start-page: 644
  year: 2012
  ident: 10.1016/j.jtct.2021.05.001_bib0004
  article-title: Human cytomegalovirus persistence
  publication-title: Cell Microbiol
  doi: 10.1111/j.1462-5822.2012.01774.x
– volume: 362
  start-page: 1375
  issue: 9393
  year: 2003
  ident: 10.1016/j.jtct.2021.05.001_bib0147
  article-title: Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines
  publication-title: Lancet
  doi: 10.1016/S0140-6736(03)14634-X
– volume: 64
  start-page: 108
  year: 1997
  ident: 10.1016/j.jtct.2021.05.001_bib0042
  article-title: Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture
  publication-title: Transplantation
  doi: 10.1097/00007890-199707150-00020
– volume: 118
  start-page: 179
  year: 1993
  ident: 10.1016/j.jtct.2021.05.001_bib0069
  article-title: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo- controlled, double-blind trial
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-118-3-199302010-00004
– volume: 101
  issue: 11
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0167
  article-title: Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide
  publication-title: Haematologica
  doi: 10.3324/haematol.2016.149880
– volume: 128
  start-page: 456
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0011
  article-title: Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia
  publication-title: Blood
  doi: 10.1182/blood-2016-04-713644
– volume: 51
  start-page: 1113
  year: 2016
  ident: 10.1016/j.jtct.2021.05.001_bib0013
  article-title: Impact of early CMV reactivation in cord blood stem cell recipients in the current era
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2016.89
– volume: 67
  start-page: 1162
  issue: 4
  year: 1986
  ident: 10.1016/j.jtct.2021.05.001_bib0155
  article-title: Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease
  publication-title: Blood
  doi: 10.1182/blood.V67.4.1162.1162
SSID ssj0002430130
Score 2.4657187
Snippet The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special...
SourceID proquest
crossref
elsevier
SourceType Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 707
SubjectTerms Cytomegalovirus
Guideline
Hematopoietic cell transplant
Preemptive therapy
Prevention
Prophylaxis
Title American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation
URI https://www.clinicalkey.com/#!/content/1-s2.0-S2666636721008927
https://dx.doi.org/10.1016/j.jtct.2021.05.001
https://www.proquest.com/docview/2566041489
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3BatwwEBWb5NJLaGlLk7RBpb0Fs7YkS3Zuy7bLpktzaBKam7BlCTZs7CXrDeSWj-gf9M_6JZmx5IWGkkBPRkYjGY08M9K8mSHksykzW4JZG1VpyiIhCxblqgJDDrQ3z-IiNl18xfdTOb0Q3y7TywEZ97EwCKsMst_L9E5ahzfDsJrD5Xw-PAPVAupSwhEG9FjO1BbZYTyXsLV3Riez6enmqoUJjv45LDMHFBHShPAZj_S6ag2iKlnS5fAM5WH-oaIeCetOA01ekt1gOtKR_7pXZGDr1-R373KhAX9JwQqlPmX5ovBxRTUt6oqO7WKBmFN67hMJULwYs6tj-on_uf_Vp3KCzo2j47u2ubagPJrb-c16RU8CZMuP9MU7degI64vTKWZ9bZbNHMMhu1keT_-GXEy-no-nUSi8EBmRxm1USZWUJrEFczapuKpcCVaGLJkspYMGSAKjeOqMclnGTcKB0YonxuQqzZmR_C3ZrpvaviM0E5m1TlgQJIWwiSilcmCUVtxVKhbO7ZGkX2ttQlZyLI6x0D387EojfzTyR8cpYvD2yNGGZulzcjzZm_cs1H20KchHDSrjSap0Q_XXfnyW7mO_SzT8qOh9KWrbrFcabEsZCzh95vv_OfYBeYEtj3B7T7bbm7X9ACZRWx6GLY_P2Y-fswcxKA9f
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELbK9gAXBAJEgRYjuKFok_gv6W21pcrSdi9spd6sxLGlrbbJqptF4sZD8Aa8GU_CTOysRIWKxDGJx4lsZ76x55sZQj6YKrMVmLVRLUQacVmmUa5qMOQAvVkWl7Hp4ysu5rK45J-vxNUemQ6xMEirDLrf6_ReW4c74zCa4_VyOf4C0AJwKWELAziWp-oB2cfsVGJE9iezs2K-O2pJOUP_HJaZA4kIZUL4jGd6XXcGWZVp0ufwDOVh_gJRd5R1j0CnT8jjYDrSif-6p2TPNs_Iz8HlQgP_koIVSn3K8lXp44oaWjY1ndrVCjmndOETCVA8GLObY_qe_fr-Y0jlBI1bR6ffuvbGAni0X5e32w2dBcqW7-nEO3XoBOuL0wKzvrbrdonhkP1b7r7-Obk8_bSYFlEovBAZLuIuqqVKKpPYMnU2qZmqXQVWhqxSWUkHF6AJjGLCGeWyjJmEwUQrlhiTK5GnRrIXZNS0jX1JaMYzax23oEhKbhNeSeXAKK2Zq1XMnTsgyTDW2oSs5FgcY6UH-tm1xvnROD86FsjBOyAfdzJrn5Pj3tZsmEI9RJuCftQAGfdKiZ3UH-vxn3LvhlWi4UdF70vZ2Ha70WBbypjD7jN_9Z99vyUPi8XFuT6fzc9ek0f4xLPd3pBRd7u1h2AeddVRWP6_AXZ1EKI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=American+Society+for+Transplantation+and+Cellular+Therapy+Series%3A+%233%E2%80%94Prevention+of+Cytomegalovirus+Infection+and+Disease+After+Hematopoietic+Cell+Transplantation&rft.jtitle=Transplantation+and+cellular+therapy&rft.au=Hakki%2C+Morgan&rft.au=Aitken%2C+Samuel+L.&rft.au=Danziger-Isakov%2C+Lara&rft.au=Michaels%2C+Marian+G.&rft.date=2021-09-01&rft.pub=Elsevier+Inc&rft.issn=2666-6367&rft.eissn=2666-6367&rft.volume=27&rft.issue=9&rft.spage=707&rft.epage=719&rft_id=info:doi/10.1016%2Fj.jtct.2021.05.001&rft.externalDocID=S2666636721008927
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2666-6367&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2666-6367&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2666-6367&client=summon